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1 Aims of the study 
In recent years, moleculargenetic methods have been improved and analyses of the 
human genome have become possible. Although humans share over 99.9% of their 
DNA sequence, 0.1% difference is enough to make every individual unique. It is 
evident that genetic factors influence our phenotypes. Genetic factors are slight 
variations in the DNA sequence, often only in the extent of the exchange of one nucleic 
base. Whereas mutations in the human genome are rare and occur in less than 1% of 
the world´s population, the term “polymorphism” signifies variations in the DNA 
sequence that are common in more than 1% of the world´s population. Polymorphisms 
appear all 100 to 1000 letters. These loci are called “alleles”. The combination of alleles 
at any variant is known as genotype, which is determined by the genetics of one´s 
parents. A genotype can be homozygote or heterozygote, whereupon homozygote 
means two copies of the same allele, independently if it is the ancestral or the variant 
allele. An individual is categorized “heterozygote” for a certain gene locus when he or 
she carries one allele of each copy (Roth, 2007). 
Much work focused on different polymorphisms that might determine physical activity 
and success in competition (Rankinen, Bray, Hagberg, Perusse, Roth, Wolfarth & 
Bouchard, 2006a). Huge analyses were carried out in endurance athletes (e.g. the 
Gen-Athlete Study, Wolfarth, 2002). Comparisons between endurance athletes and 
sprinters or other power athletes were also performed (Yang, MacArthur, Wolde, 
Onywera, Boit, Lau, Wilson, Scott, Pitsiladis & North, 2007 and others more) as well as 
training studies with sedentary individuals (e.g. the HERITAGE Family Study, 
Bouchard, Leon, Rao, Skinner, Wilmore & Gagnon, 1995). Although even in athletes 
that can be easily assigned to either endurance or strength dominated sports, the 
influence of certain gene polymorphisms is discussed due to contradictory data 
published (Rankinen et al., 2006a). In complex sports as skiing the influence of genetic 
determinants on success in competition is even more difficult to prove. Nevertheless, it 
is supposed that there are heritable factors that have an impact on skiing performance. 
We speculated that there are gene variants or gene variant constellations that favour 
success in competition. Therefore, we aimed to screen for some selected gene variants 
in alpine skiers and sedantary controls to assess demonstrative differences in the 
frequency of performance-related genotypes between study groups. Five 
polymorphisms were planned to be analysed, whereof two had been well described in 
literature and three of them had been underrepresented in published data. As we could 
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unfortunately not get a representative sample of alpine skiers, the new aproach was to 
compare performance-related genotypes between sedentaries, active people and 
endurance athletes. For polygenic effects, the concept of the Totale Genotype Score 
(TGS) originally developed by Williams and Folland (2008) should be used. To optimize 
and ease sample collection and DNA isolation, different methods were compared in 
order to find a preferably cheap, fast and for the probands as easy as possible one. 
In fact, the work is part of a huge genotype project, which aimed to compare genotype 
frequencies of over 20 performance-related polymorphisms between sedentaries and 
athletes of endurance-, strength-dominated, and complex sport disciplines, 
respectively. 
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2 Literature review 
Until now, genetic variants among excellent alpine skiers have not been described in 
published data. Only Druzhevskaya, Ahmetov, Astratenkova & Rogozkin (2008) included 
alpine skiers in their analyses as a subgroup of power athletes. On the one hand, it can be 
assumed that there are certain heritable factors that favour success in skiing competitions 
and that the frequency of these favouring gene variants is higher in elite skiers than in 
sedentary controls. On the other hand skiing is a complex sport and it is not completely 
clear which skills are crucial for a high skiing performance. A genetic profile can be helpful 
identifying such performance-determining parameters in skiers.  
As already mentioned there exist a huge number of genetic variants throughout the 
human genome and a part of them is discussed as co-determining factors for physical 
performance. In fact, there are different types of genetic variants known and the location 
of the polymorphism is important to its possible impact (Roth, 2007). The most common 
type of genetic variants is a single nucleotide polymorphism (SNP). In this case, only one 
nucleic base is changed, for example an adenine (A) is replaced by a guanine (G). 
Another type is an insertion/deletion (I/D) polymorphism. The insertion allele includes a 
strech of specific DNA nucleotides, whereas this part is not present at the deletion allele. 
The third group of polymorphisms are microsatellite repeats (MS). Short DNA stretches of 
two or three nucleic bases are repeated at different frequencies. The number of repeats in 
the DNA stretch identifies the allele. Whereas SNPs and I/Ds have only two different 
possible alleles, the length of the repeat polymorphism is highly variable and different 
repeat frequencies are grouped together (Roth, 2007). For example, the IGF1 gene 
carries a MS polymorphism with 11 to 24 repeats reported, but alleles are identified as 19 
microsatellite repeats or repeat numbers different from 19  (see 2.1.2.1). 
2.1 Selected polymorphisms related to physical activity and 
performance 
Since the 1990s sport sciences have begun to focuse on the impact of gene variants on 
performance and fitness parameters (Rankinen, Perusse, Rauramaa, Rivera, Wolfarth & 
Bouchard, 2001). The magnitude of genetic determination for success in different sports 
remains unknown but heritability for VO2max is estimated 25-40% (Wolfarth, Boulay, 
Perusse, Rankinen, Rauramaa, Rivera & Bouchard, 2001). The human gene map for 
performance and health-related fitness phenotypes annually summarizes candidate 
genes, which may be partly responsible for performance and fitness parameters 
(Rankinen et al., 2001; Rankinen, Perusse, Rauramaa, Rivera, Wolfarth & Bouchard, 
2002; Perusse, Rankinen, Rauramaa, Rivera, Wolfarth & Bouchard, 2003; Rankinen, 
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Perusse, Rauramaa, Rivera, Wolfarth & Bouchard, 2004; Wolfarth, Bray, Hagberg, 
Perusse, Rauramaa, Rivera, Roth, Rankinen & Bouchard, 2005; Rankinen et al., 2006a). 
The human obesity gene map contains genes that might be responsible for body weight 
and health parameters related to adiposity and nutritional status (Rankinen, Zuberi, 
Chagnon, Weisnagel, Argyropoulos, Walts, Perusse & Bouchard, 2006b).  
Only few analyses dealt with the interaction of a couple of candidate genes and their 
impact on performance. The comparison of genetic variants of nine world-class cross-
country runners and the cross-country world champion 2007 in seven candidate genes 
highlighted preferable variants concerning endurance performance (Gonzalez-Freire, 
Santiago, Verde, Lao, Oiivan, Gomez-Gallego & Lucia, 2008). Among others the gene 
coding for α-actinin-3 (ACTN3), the muscle-specific creatine kinase gene (CKMM) and the 
myostatin gene (MSTN) were selected and the theoretically optimal genotype for 
endurance performance was determined (Gonzalez-Freire et al., 2008).  
The comparison of the genotype of rowers, runners, road cylclists, and controls in the 
seven gene variants (ACTN3, angiotensin-converting enzyme (ACE), peroxisome 
proliferators-activated receptor γ coactivator 1α, adenosine-monophosphate deaminase, 
CKMM, MSTN) revealed no significant differences between groups except for the ACE 
gene variant (Muniesa, Gonzalez-Freire, Santiago, Lao, Buxens, Rubio, Martin, Arenas, 
Gomez-Gallego & Lucia, 2008). 
In the Genathlete Study (Wolfarth, 2002) endurance trained athletes were compared with 
sedentary controls concerning gene variants in the ACE, the erythropoietin receptor, the 
CKMM, the endothelial nitrooxid synthetase, and the α-2A-adrenergic receptor gene and 
others more. Results differed between the selected candidate genes. For example, 
variants in the erythropoietin receptor gene seemed to have an impact on VO2max in the 
study population whereas for the polymorphism in the CKMM gene no differences 
between study groups were observed (Wolfarth, 2002).  
The following selected genes and their described variants were repeatedly discussed in 
their involvement in endurance or strength performance, carbohydrate metabolism, and 
physical activity but most published data is controverse and does not allow to draw clear 
conclusions.  
2.1.1 Alpha-actinin-3 
One of the best-described polymorphism is the R577X variant (rs1815739) in the gene 
coding for α-actinin-3 (ACTN3) (Macarthur & North, 2005). Its impact on physical 
performance is evident according to an emerging number of analyses (Yang et al., 2007; 
Literature review 
 
 5 
Ahmetov, Druzhevskaya, Astratenkova, Popov, Vinogradova & Rogozkin, 2008; 
Druzhevskaya et al., 2008, and others more).  
ACTN3 is one of four α-actinin isoforms present in the human organism. Whereas ACTN1 
and ACTN4 are non-muscle cytoskeletal, calcium-sensitive isoforms, ACTN2 and ACTN3 
are present in muscle tissue and act calcium independently. Both muscle α-actinin 
isoforms are coded by different genes and they have been highly conserved through 
evolution. The two muscle-specific isoforms are 80% identical and 90% similar, but 
whereas ACTN2 is present in all muscle fibers, ACTN3 is exclusively expressed in fast 
twitch (type FT 2b) muscle fibers. ACTN3 is a predominant component of the Z-discs in 
type-II-muscle fibers where it anchors actin filaments of the muscle contractile apparatus 
(North, Yang, Wattanasirichaigoon, Mills, Easteal & Beggs, 1999; Mills, Yang, 
Weinberger, Vander Woude, Beggs, Easteal & North, 2001; MacArthur & North, 2004).  
Two mutations were highlighted in the ACTN3 gene during research on muscle diseases. 
The Q523R variant (rs1671064) is an A to G transition in exon 15 and is in strong linkage 
disequilibrium to the R577X polymorphism (rs1815739), which is a C to T transition in 
exon 16 at residue 577. The R577X variant results in a conversion from an arginine to a 
stop codon. The presence of the stop codon causes complete ACTN3 deficiency. 
Nowadays it is clear that the null allele variant (X-allele) does not result in any pathological 
phenotype but that it has an impact under certain conditions. About 16% of people 
worldwide carry the XX null genotype and are therefore ACTN3 deficient. It is speculated 
that in case of ACTN3 deficiency, ACTN2 can compensate for the missing ACTN3 (North 
et al., 1999; Mills et al., 2001; MacArthur & North, 2004). The frequency of the XX null 
genotype strongly differs among ethnic groups (North et al., 1999; Yang et al., 2007). 
2.1.1.1 ACTN3 R577X (rs1815739) variant and elite athlete status 
An Australian cohort consisting of 436 controls, 194 elite endurance athletes as well as 
107 sprint and power athletes was screend for their genotype in the ACTN3 gene (Yang, 
MacArthur, Gulbin, Hahn, Beggs, Easteal & North, 2003).  The RR genotype and the R-
allele were significantly higher in female and male sprint athletes than in controls and 
endurance athletes. The XX genotype was found to be slightly higher in endurance 
athletes than in controls. As there were no differences between the control and the whole 
athlete group, it seems as the genotype in the sprint/power and endurance group deviated 
in opposite directions and cancelled each other out. The high frequency of the RR 
genotype among sprinters and power athletes could be due to an advantageous effect of 
this genotype on power performance (Yang et al., 2003). 
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A Finnish study cohort (Niemi & Majamaa, 2005) consisted of 141 elite athletes, among 
them 40 endurance specialists, 68 sprint athletes and 120 athletes that could not be 
clearly related to either sprint or endurance dominated sportsmen. Over 1,000 subjects 
served as control population. The XX genotype was significantly higher in the endurance 
and the control subgroups than in sprinters indicating an inverse correlation between 
sprinting performance and the XX genotype. Among the top-level sprinters (participants of 
European or World Track and Field Championships), no one carried the XX genotype. 
Controversely, there were no differences in the ACTN3 genotype found between world-
class runners, cyclists, lightweight rowers and a Spain male control group (Muniesa et al., 
2008). In a qualitative comparison of seven top endurance runners, the RR or the RX 
genotype turned out as the theoretically favourable genotype for success. Among nine 
top-level cross-country runners (finished at least under the best twenty participants of the 
Cross-Country World Championship for more than one time on the long distance), eight of 
them carried the RR or RX genotype including the world champion 2007 (Gonzalez-Freire 
et al., 2008). 
In a Greek cohort of 181 control subjects and 101 track and field athletes no significant 
differences between the groups could be detected, not even when the athlete group was 
divided into power and endurance oriented athletes (Papadimitriou, Papadopoulos, 
Kouvatsi & Triantaphyllidis, 2008). Interestingly, when the power athlete group was further 
divided, a significant higher frequence of the RR genotype as well as a significant lower 
frequence of the XX genotype was found in the subgroup of only sprint athletes 
(Papadimitriou et al., 2008). These results were confirmed by the outcomes of Moran, 
Yang, Bailey, Tsiokanos, Jamurtas, MacArthur, North, Pitsiladis and Wilson (2007). They 
screend adolescent Greeks for their genotype in the ACTN3 gene as well as for body 
composition and power/strength related phenotypes. An association with the genotype 
was only found in male participants for the 40-meter sprint time. Carriers of the XX 
genotype had significantly lower sprint times and therefore ran faster. As there were no 
associations found for endurance tests and other power-related tests (e.g. vertical jump, 
sitting basket throw, handgrip strength) except the 40-meter sprint with the ACTN3 
genotype, the researches speculated that the ACTN3 RR genotype favours power 
generation by repeated cycles of muscle contraction and not force caused by a single 
muscle contraction (Moran et al., 2007). However, in white and black elite body builders 
and power lifters the XX genotype was significantly underrepresented in white and not 
present in black strength athletes (Roth, Walsh, Liu, Metter, Ferrucci & Hurley, 2008).  
Studying a Nigerian cohort of control subjects and power athletes revealed no differences 
between both groups (Yang et al., 2007). As there was neither a control individual carrying 
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the XX genotype nor any of the power athletes, this genotype distribution could mask any 
genotype effects between the two cohorts. Results confirm different genotype distributions 
in different ethnic groups (Yang et al., 2007). 
In 468 Caucasian athletes of different power-oriented sports the XX genotype and the X-
allele were found in a significantly lower frequency than in about 1,200 Russian control 
subjects (Druzhevskaya et al., 2008) 
Until today, it is not completely clear why ACTN3 deficiency does impair sprint 
performance, because the null variant does not have any implications in activities of 
normal living (North et al., 1999). In mouse models, it seems as ACTN3 deficiency results 
in a more efficient muscle metabolism that may favour endurance performance (North, 
2008). However, also the high congential fiber type distribution could be influenced by the 
ACTN3 genotype and would explain the strong association with power/sprint performance 
(Vincent, De Bock, Ramaekers, Van den Eede, Van Leemputte, Hespel & Thomis, 2007).  
Fortyfour of 90 ACTN3 genotyped and strength tested healthy men underwent a muscle 
biopsy of the m. vastus lateralis. RR homozygotes had significantly higher dynamic 
quadriceps´ torques and greater type IIx fibers than carriers of two nonsense alleles (XX). 
Furthermore, it was found that the proportion of ACTN3 was higher in type IIx fibers than 
in type IIa fibers (Vincent et al., 2007). Controversely, North et al. (1999) did not find any 
impact of the ACTN3 polymorphism on fiber distribution in their initial sample of 125 
genotyped and muscle-biopsied subjects. However, it is documented that ACTN2 does 
not completely overlap ACTN3 expression and that the ACTN2 to ACTN3 ratio varies 
between different muscle fiber types in mice (Mills et al., 2001). 
As some study results indicated that there could be a favourable effect of the ACTN3 XX 
genotype on endurance performance (Yang et al., 2003; Niemi & Majamaa, 2005), further 
research was applied on this subject. ACNT3 R577X genotype was determined in 50 
professional Spain cyclists, who had finished at least one of the three 3-week stage races 
Tour de France, Giro d´Italia and Vuelta a Espana, in 52 middle-distance runners who 
participated in Olympic games and in 123 Caucasian male controls (Lucia, Gomez-
Gallego, Santiago, Bandres, Earnest, Rabadan, Alonso, Hoyos, Cordova, Villa & Foster, 
2006). Additionally, the gas exchange ration was measured using open circuit spirometry 
during an all-out test to determine endurance performance. The three study groups did not 
differ from each other concerning their genotype contribution indicating that the XX 
genotype does not have any advantageous effect on endurance performance (Lucia et al., 
2006).   
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Since modern middle distance and marathon running is dominated by East Africans, Yang 
et al. (2007) genotyped 350 Ethiopian and Kenyan elite runners as well as 356 
corresponding controls for the R577X polymorphism. Ethiopians and Kenyans both 
athletes and control subjects differed in their genotype contribution. Whereas the XX 
genotype was present in 11% of Ethiopians, only 1% of the Kenyans carried the ACTN3 
null genotype. In both study populations, the frequency of the XX genotype was lower 
than in European samples. No differences between the athlete and control subjectes were 
found; neither in Ethiopians nor in Kenyans. After splitting the cohorts into male and 
female subjects, an genotype effect was neither found (Yang et al., 2007). 
Genotype frequency of elite Italian rowers did not significantly differ from controls either 
concerning the R577X polymorphism or the Q523R variant (rs1671064) in the ACTN3 
gene (Paparini, Ripani, Giordano, Santoni, Pigozzi & Romano-Spica, 2007). Therefore, 
authors concluded that both polymorphisms did not influence endurance performance in 
men (Paparini et al., 2007). The same results were obtained in 457 Caucasian male 
triathletes who competed in an Ironman Triathlon. Their ACTN3 R577X genotype 
distribution did not significantely vary from 143 healthy Caucasian men (Saunders, 
September, Xenophontos, Cariolou, Anastassiades, Noakes & Collins, 2007). 
In 556 Russian athletes competing in endurance-oriented sports ACTN3 R577X genotype 
frequencies were determined as well as in about 1,200 healthy controls (Ahmetov et al., 
2008). Whereas the control study group did not differ from the calcutated genotype 
frequency in Hardy-Weinberg equilibrium1, the athletes´ genotype distribution was 
significantly different from the predicted one. The XX genotype and the X-allele were 
significantly underrepresented in endurance athletes compared with Hardy-Weinberg 
equilibrium as well as with controls. It is speculated that even if the ACTN3 577X 
genotype may confer an advantageous effect for the aerobic metabolism (Ahmetov et al., 
2008; North, 2008), in modern endurance sport at the international top level, also forthful 
muscle contractions at high velocities are necessary for success (Lucia et al., 2006; 
Ahmetov et al., 2008). 
2.1.1.2 ACTN3 R577X variant (rs1815739) and response to training 
As the anteceded chapter focused on the ACTN3 R577X genotype (rs1815739) and elite 
athlete status, the genotype effect on physical performance was also highlighted in 
untrained individuals, often in combination with a training intervention: 
                                                   
1
 The Hardy-Weinberg Equilibrium theorem was assessed to calculate the behaviour of two alleles 
at a single gene locus in a study population. Nowadays it is used in association studies to detect 
genotyping errors and to disease susceptibility (Ryckman & Williams, 2008, p. 1) 
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Walsh, Liu, Metter, Ferrucci and Roth (2008) screend 848 subjects aged from 22 to 90 
years for their genotype of the ACTN3 R557X polymorphism and strength in the knee 
extensor muscle. Lower eccentric and concentric strength levels were found in XX 
homozygotic women as well as lower FFM. No differences between genotype groups and 
strength values were documented in men (Walsh et al., 2008).  
In a training study, initial strength was evaluated in about 600 genotyped subjects 
(Clarkson, Devaney, Gordish-Dressman, Thompson, Hubal, Urso, Price, Angelopoulos, 
Gordon, Moyna, Pescatello, Visich, Zoeller, Seip & Hoffman, 2005). After a strength-
training period of 12 weeks, strength measurements were repeated. In the male subgroup, 
no differences between baseline strength and response to training were found between 
genotype groups, whereas in females ACTN3 577X homozygotes had the lowest baseline 
strength levels. Interestingly, the highest values were not found in RR individuals but in 
heterozygotes. After the training period females carrying the XX genotype had the highest 
increases in 1RM absolute strength as well as relative to their body weight (Clarkson et 
al., 2005). 
In contrast, in 102 genotyped elderly no differences in baseline strength could be detected 
concerning the ACTN3 R577X genotype either in men or in women (Roth, Delmonico, 
Rabon-Stith, Karma, Walsh & Hurley, 2005). In response to a 10-week strength-training 
program, XX homozygotic and heterozygotic men increased their relative and absolute 
peak power significantly less than RR homozygotes. No differences were observed in 
females (Roth et al., 2005). Whereas Roth et al. (2005) trained the knee extensor muscle, 
Clarkson et al. (2005) focused on the elbow flexor. 
In 120 trained individuals, no association between the ACTN3 R577X genotype with 30-s 
Wingate cyling as well as with knee extensor strength and fatigability during isokinetic 
exercise was found (Norman, Esbjornsson, Rundqvist, Osterlund, von Walden & Tesch, 
2009). As there were differences between RR and XX homozygotes in the peak torque 
after repeated bouts of exercise found, it was speculated that the polymorphism would 
influence training response. Additional muscle biopsies revealed an association between 
the polymorphism and the ACTN2 expression indicating that ACTN2 may compensate for 
the lack of ACTN3 in carriers of the stop codon (X). No differences in the muscle fiber 
composition was observed between genotype groups (Norman et al., 2009).  
2.1.2 Insulin like growth factors 
Insulin like growth factors (IGFs) are polypeptides that share structural and functional 
homologies with insulin. Whereas the insulin like growth factor 1 (IGF1) is regulated by the 
growth hormone, the insulin like growth factor 2 (IGF2) is not affected by the growth 
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hormone. In fact, the primary regulator of IGF2 expression remains unknown. Several 
other hormones, as for example estrogens and andrenocorticotropic hormone, have an 
impact on IGF levels as well as nutrition (Yu & Rohan, 2000). 
IGF1 has an anabolic effect via an increased amino acid and glucose uptake into the cell. 
IGF1 further regulates cell proliferation, cell differentiation and cell apoptosis. IGF1 levels 
increase until puberty and decline with age thereafter (Yu & Rohan, 2000; Allen, Davey, 
Key, Zhang & Narod, 2002; Canzian, McKay, Cleveland, Dossus, Biessy, Rinaldi, Landi, 
Boillot, Monnier, Chajes, Clavel-Chapelon, Tehard, Chang-Claude, Linseisen, Lahmann, 
Pischon, Trichopoulos, Trichopoulou, Zilis, Palli, Tumino, Vineis, Berrino, Bueno-de-
Mesquita, van Gils, Peeters, Pera, Ardanaz, Chirlaque, Quiros, Larranaga, Martinez-
Garcia, Allen, Key, Bingham, Khaw, Slimani, Norat, Riboli & Kaaks, 2006).  Since IGF1 
enhances mitosis, it is discussed as parameter for fat free mass (FFM) and muscle 
strength (Sun, Gagnon, Chagnon, Perusse, Despres, Leon, Wilmore, Skinner, Borecki, 
Rao & Bouchard, 1999; Kostek, Delmonico, Reichel, Roth, Douglass, Ferrell & Hurley, 
2005; Lopez-Alarcon, Hunter, Gower & Fernandez, 2007) and therefore it is an interesting 
parameter concerning physical activity and performance.  
Like IGF1, IGF2 has an impact on cell proliferation and differentiation and a mitogenic and 
antiapoptotic effect but it is supposed that IGF2 plays a major role in prenatal 
development and growth. Both IGF1 and IGF2 mediate their effects through binding to the 
same receptor, the IGF-1 receptor (Yu & Rohan, 2000). Several studies focused on the 
hypothesis that variation in the IGF2 gene is associated with interindividuell differences in 
body mass and muscle strength across the adult life span (Schrager, Roth, Ferrell, Metter, 
Russek-Cohen, Lynch, Lindle & Hurley, 2004; Devaney, Hoffman, Gordish-Dressman, 
Kearns, Zambraski & Clarkson, 2007). In this context, IGF2 gene variants may become 
important for the determination of physical performance.  
2.1.2.1 Genetic variants in the IGF1 gene 
Interindividual differences in serum IGF1 levels are high and are considered to be 
determined by 60% by genetic factors (Hong, Pedersen, Brismar, Hall & de Faire, 1996).  
However, there are controversial results published dealing with genetic variants in the 
IGF1 gene and their effects on different phenotypes (Table 1). 
Table 1: Genetic variants in the IGF1 gene and their effects on different phenotypes 
CA dinucleotide repeat (MS): 19>≠19 tandem repeats in the promoter  
Allen et al. (2002) No impact on circulation IGF1 plasma levels in Caucasian men 
Jernstrom et al. (2001) Higher IGF1 serum levels in noncarriers of the 19 allele but only in 
women using oral contraceptive 
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Kostek et al. (2005) Greater increases in muscle strength and muscle volume after 
training in carriers of the 19 CA allele in older adults 
Morimoto et al. (2005) No impact on circulation IGF1 plasma levels in Caucasians 
Rosen et al. (1998) Significant lower IGF1 serum levels in homozygotes of the 19 CA 
allele 
Vaessen et al. (2001) Significant higher body height and IGF1 serum levels in 
homozygotes of the 19 CA allele 
Van Heemst et al. (2005) 
Trend (not significant) for lower body height and relative mortality 
risk in female inhabitants of The Netherlands carrying the non-
dominant (≠19) allele (lower IGF1 levels) 
CT dinucleotide repeat (MS): 189bp>≠189bp tandem repeats in the 5´ region 
Lopez-Alarcon et al. (2007) 
European and African-American femal noncarriers (≠189bp) seem to 
be predisposed to higher leg muscle mass but to worse endurcance 
and energy economy 
Sun et al. (1999) 
Lower baseline levels of BMI, fat mass, percent body fat, and FFM 
and  lower FFM gains in response to areobic training in 189bp-
homozygotic Caucasians 
Van Heemst et al. (2005) No impact on insulin/IGF1 singalling pathwas or longevity in elderly 
Dutch 
rs2162679 (SNP): A>G in the intron 
Canzian et al. (2006) No impact on circulating IGF1 plasma levels in Caucasian women 
rs35765 (SNP): C>A in the promoter region 
Canzian et al. (2006) No impact on circulating IGF1 plasma levels in Caucasian women 
rs35767 (SNP): C>T in the promoter region 
Canzian et al. (2006) No impact on circulating IGF1 plasma levels in Caucasian women 
Devaney et al. (2007) No impact on muscle regeneration after bouds of eccentric strength 
training in Caucasians 
rs6214 (SNP): C>T in on Exon 4, 3´UTR 
Canzian et al. (2006) No impact on circulating IGF1 plasma levels in Caucasian women 
rs6220 (SNP): T>C in on Exon 4, 3´UTR 
Canzian et al. (2006) No impact on circulating IGF1 plasma levels in Caucasian women 
bp – base pairs, MS - microsatellite polymorphism, SNP - single nucleotide polymorphism, UTR - 
untranslated region 
In a huge study breast cancer risk was correlated with genetic factors including variants in 
the IGF1 gene and their effects on IGF1 plasma levels (Canzian et al., 2006). The 
population studied included about 2,400 women with the majority of Caucasian origin. 
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None of the five examined SNPs (rs35765, rs35767, rs2162679, rs6220, rs6214) revealed 
a significant association with serum IGF1 levels (Canzian et al., 2006). 
Effects of eccentric strength burden on muscle repair mechanisms were compared 
between 156 individuals (half of them women) genotyped for various SNPs in the IGF1, 
IGF2, and IGF-binding protein genes (Devaney et al., 2007). Nearly three-quarter were of 
Caucasian origin. In the IGF1 gene, only one SNP (rs35767/-C1245T) in the promoter 
region was analyzed but no association was found (Devaney et al., 2007). 
Another study group hypothesised that higher IGF1 levels are linked to premenopausal 
breast cancer risk (Jernstrom et al., 2001). The study population consisted of 503 
premenopausal women of the ethnic groups white, black, Asian, and Indian-Pakistani. The 
intake of an oral contraceptive was assessed too due to the possible impact of exogenous 
estrogens on the IGF1 plasma levels. Genotyping also included a cytosine-adenine (CA) 
tandem repeat polymorphism (microsatellite polymorphism) in the IGF1 promoter region. 
Genetic variants of the CA microsatellite polymorphism are usually divided into carriers of 
19 tandem repeats and noncarriers of the 19 repeat allele, because 19 tandem repeats 
are the most common variant, whereas alleles from 11-24 CA repeats are reported 
(Weber & May, 1989; Allen et al., 2002).  Results show an association between 
noncarriers of the 19 repeat allele and higher IGF1 levels, but only in women using oral 
contraceptives. No association could be detected in women that do not apply exogenous 
estrogens.  
Contrary to these results Allen et al. (2002) found no association between the CA 
microsatellite polymorphism and IGF1 serum levels in nearly 700 Caucasian men.  
In 129 middle-aged men and 194 women major of Caucasian origin, the CA microsatellite 
polymorphism was linked neither to IGF1 serum levels nor to physical activity in the study 
population but there was an association with IGF binding protein 3 levels (Morimoto et al., 
2005).  
In a sub-study of the Rotterdam study, 900 men and women aged averagely 65.9 years 
were screend for anthropometric variables and the CA repeat polymorphism in the IGF1 
gene (Vaessen et al., 2001). Further, the association between that polymorphism and type 
2 diabetes as well as myocardial infarction was examined. Individuals homozygotic for the 
19 CA allele had a significant higher body weight and significant higher serum IGF1 levels 
than noncarriers or heterozygotes. The relative risk (Odds Ratio) for a type 2 diabetes 
mellitus was 1.7 in noncarriers of the 19 CA repeat allele and 1.4 in heterozygotes. The 
relative risk for a myocardial infarction was 70% elevated for noncarriers and 20% for 
heterozygotes (Vaessen et al., 2001).  
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Serum IGF1 levels were also analysed in 171 Caucasians to highlight an association 
between the IGF CA microsatellite polymorphism and bone mineral density (Rosen et al., 
1998). Contrary to the results of Vaessen et al. (2001), in this study cohort IGF1 serum 
levels were significantly decreased in 19 CA homozygotes.  
67 healthy but inactive Caucasians over 50 years of age were screened for their 
genotypes in the IGF1 gene as well as for anthropometric parameters (Kostek et al., 
2005). The subjects completed strength training for the knee extensor on one leg for 10 
weeks and the training response was linked to the genotype. Variants examined were the 
SNPs rs19779, rs40395, and rs82681 as well as the CA microsatellite polymorphism. 
None of the four SNPs examined revealed any association with anthropometric 
measurements, initial strength, or training response. Initial strength (One repetition 
maximum, 1RM) was not significantly different between genotype groups but the increase 
of strength was significantly higher in carriers of the 19 CA allele. The presence of one or 
two alleles of the 19 CA repeats did not affect strength increase. Furthermore, there was a 
significant higher increase in muscle volume in 19 CA carriers than in individuals missing 
the 19 CA allele. Improvements in muscle quality, defined as strength in Newtons per 
muscle volume, were not different between genotype groups (Kostek et al., 2005).  
Van Heemst, Beekman, Mooijaart, Heijmans, Brandt, Zwaan, Slagboom & Westendorp 
(2005) examined the impact of various genetic variants on the mortality risk of humans. In 
the analysis of 1,245 elderly inhabitants of The Netherlands, two microsatellite 
polymorphisms in the IGF1 gene were included -  the CA repeat polymorphism as well as 
the cytosine-thymidine (CT) repeat polymorphism in the 5´ region (Sun et al., 1999) of the 
IGF1 gene. There was a significant impact neither of the CT nor of the CA genotype on 
examined phenotypes (insulin/IGF1 signalling pathway). Nevertheless, a trend for the CA 
microsatellite polymorphism was found for lower body height and lower relative mortality 
risk due to a reduced insulin signalling pathway only in females (van Heemst et al., 2005).  
The CT dinucleotide repeat polymorphism was also discussed to be responsible for 
interindividual responses to aerobic exercise training (Sun et al., 1999). The hypothesis 
was that differences of the IGF1 levels due to genetic variants would influence training 
induced changes in body composition. The study population consisted of 99 Caucasian 
families (502 healthy and sedentary subjects; HERITAGE Family Study) who followed an 
exercise-training program on a cycle ergometer for 20 weeks. Fat mass, percent of body 
fat, body mass index (BMI), fat free mass (FFM), and abdominal visceral fat were chosen 
as parameters for body compositon. At baseline, 189bp homozygotes had significant 
lower levels for BMI, fat mass, FFM and percent body fat but in response to the conducted 
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aerobic training, they gained only half of the amounts of FFM in comparison to 189bp non-
homozygotes and heterozygotes (Sun et al., 1999).   
Lopez-Alarcon et al. (2007) compared body composition (FM, lean body mass (LBM), arm 
fat mass, leg fat mass, nonbone arm, leg lean mass), exercise performance (endurance 
time on the treadmill during a VO2max test), and exercise economy (submaximal VO2 
measurement during stairclimbing and cycling) in premenopausal sedentary African-
American and European-American women genotyped for the IGF1 CT microsatellite 
polymorphism. Participants´ characteristics were comparable between genotypes. 
However, noncarriers of the 189bp allele had higher values of nonbone arm, leg lean 
mass and absolute oxygen uptake during cycling. No racial differences were observed. 
Results indicate a genetic predisposition to better endurance and exercise economy in 
individuals carrying the 189bp allele in the IGF1 gene. Simultanously they might have a 
disposition to lower leg muscle mass (Lopez-Alarcon et al., 2007).  
2.1.2.2 IGF1 and its antagonist 
As IGF1 is a human growth factor, its expression has to be regulated to avoid excessive 
tissue growth. In heart myostatin demonstrated to be this regulating factor acting as an 
chalone2 (Shyu, Ko, Yang, Wang & Kuan, 2005).  Myostatin is a known negative regulator 
of muscle growth belonging to the transforming growth factor (TGF) β family (see chapter 
2.1.3). The expression of myostatin is discussed to be influenced by genetic variance like 
IGF1 expression and it is directly linked to the IGF1 signalling pathway (Gaussin & Depre, 
2005). The interaction of IGF1 and myostatin is well described by Shyu et al. (2005) and 
Gaussin & Depre  (2005). Whereas IGF1 is important for cardiac cell growth, it 
simultaneously activates the expression of myostatin, which constitutes as negative 
feedback mechanism. When IGF1 levels exceed physiological levels of hypertrophy, 
myostatin expression is upregulated and reduces muscle growth (Gaussin & Depre, 
2005). The dependent expression regulation of myostatin and IGF1 is important for the 
balance of muscle growth as shown in Figure 1. 
 In fact, the process of regulation is much more complex than it is shown in the above 
model. Training studies did not always find elevated IGF1 levels after resistance training 
that aimed to enhance muscle hypertrophy (Walker, Kambadur, Sharma & Smith, 2004). 
Myostatin levels were decreased after strength training in the same study population but 
there were no differences between strength training limited to the elbow flexor muscle and 
a whole body workout. These results indicate that effects of IGF1 and myostatin may not 
only be mediated through central regulation mechanisms but also or perhaps basically 
                                                   
2
 A “chalone” is an “agent, that acts as tissue-specific mitotic inhibitor in the manner of a negative 
feedback mechanism” (Bullough, 1965, p. 1692). 
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through autocrine-paracrine actions (Walker et al., 2004).  
Moderate IGF1 levels   adaptive hypertrophy 
Excessive IGF1 levels   pathophysiological hypertrophy        myopathy 
       
                                                           Protection mechanism 
Stimulation of myostatin expression  reduction of hypertrophy 
Figure 1: IGF1 and its chalone myostatin (based on Gaussin & Depre, 2005) 
Analysing effects of polymorphisms within the insulin-signalling pathway, an interaction of 
the CA microsatellite polymorphism in the IGF1 gene and a novel MSTN polymorphism  
concerning the development of an athlete´s heart was found (Karlowatz, Scharhag, 
Rahnenfuhrer, Schneider, Jakob, Kindermann & Zang, 2009). In 75 male endurance 
athletes, homozygotes of the 19 CA allele in the IGF1 gene had significant lower left 
ventricular masses than heterozygotes or homozygotes of the variant alleles. The 
IVS+88_90delA polymorphism in the MSTN gene, which was described for the first time, 
also showed an impact: athletes carrying the one deletion allele (A/-) had significant lower 
left ventricular masses than homozygotes of the ancestral allele (A/A). Lower levels in 
homozygotes of the deletion allele (-/-) incomparison to AA carriers were not significant. 
Individuals who carried the IGF1 CA 19/19 polymorphism and the MSTN A/- 
polymorphism had significant lower left ventricular masses than non-carriers of the 
combination did and differences were greater than effects of the single polymorphisms. 
Further, a role of a polymorphism in the IGF1 receptor gene was reported. No impact of 
polymorphisms was described in female endurance athletes nor in male control subjects 
but sample sizes were with 35 and 27 subjects, respectively, small (Karlowatz et al., 
2009). 
2.1.2.3 IGF2 
Genetic variants in the IGF2 gene are discussed to be linked to body weight, adiposity 
and glucose tolerance (O'Dell, Miller, Cooper, Hindmarsh, Pringle, Ford, Humphries & 
Day, 1997) as well as to muscle mass and strength (Schrager et al., 2004). The most 
commonly analyzed polymorphism in this context is the ApaI polymorphism in the 3´-UTR 
of the IGF2 gene with the ancestral G-allele and the A-allele as variant (Gaunt, Cooper, 
Miller, Day & O'Dell, 2001; Schrager et al., 2004). The polymorphism is also described as 
SNP 820G/A (Gaunt et al., 2001), SNP G17200A, and rs680 (Devaney et al., 2007). Table 
2 gives an overview on different used nomenclatures and on effects of various 
polymorphisms in the IGF2 gene. 
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Table 2: Genetic variants in the IGF2 gene and their effects on different phenotypes 
ApaI polymorphism (rs680; SNP): G>A in the 3´-UTR; synonyms: 820G/A, G17200A 
Devaney et al. (2007) Higher extend of parameters of muscle damage in men homozygotic 
for the A-allele 
Gaunt et al. (2001) Significant lower BMI values in AA homozygotes  
O'Dell et al. (1997) Significant lower body weight and higher serum IGF2 in Caucasian 
AA homozygotic men 
Sayer, Syddall, O'Dell, Chen, 
Briggs, Briggs, Day and 
Cooper (2002) 
Higher IGF2 serum levels in AA homozygotes; by trend (not 
significant) higher body height and weight in GG homozygotic men 
and in AA homozygotic women; no impact on adult grip strength 
Schrager et al. (2004) Higher grip strength levels in GG women; Lower FFM in AA women; 
no genotype effects were found in men 
AluI polymorphism (SNP): T>C on exon 3; synonyms: 1252T/C 
Gaunt et al. (2001) No effects on BMI 
rs2230949 (SNP): C>T at position 16646 in the 3´-UTR 
Devaney et al. (2007) Higher extend of parameters of muscle damage in men homozygotic 
for the C-allele 
rs3213216 (SNP): G>A at position 12655 in the 1st intron 
Devaney et al. (2007) No impact on the response after strength training 
rs3213220 (SNP): T>C at position 13705 in the 1st intron 
Devaney et al. (2007) Higher extend of parameters of muscle damage in heterozygotic 
women 
rs3213221 (SNP): C>G at position 13790 in the 1st intron 
Devaney et al. (2007) Higher extend of parameters of muscle damage in men homozygotic 
for the G-allele 
rs4244808 (SNP): A>C at position 1364 in the 1st intron 
Devaney et al. (2007) Higher extend of parameters of muscle damage in men homozygotic 
for the G-allele 
rs7924316(SNP): G>T at position 11711 in the 3-Downstream region 
Devaney et al. (2007) 
Highest extend of parameters of muscle damage in AA men and 
heterozygotic women in comparison to the other gender and 
genotype groups 
SNP on nucleotide 1156: T>C in exon 3 of the IGF2 gene (GenBank accession no.: Y13633) 
Gaunt et al. (2001) Significant higher BMI values in CC homozygotes 
Literature review 
 
 17 
SNP on nucleotide 1926: C>G in exon 7 of the IGF2 gene (GenBank accession no.: X07868) 
Gaunt et al. (2001) Significant lower BMI values in GG homozygotes 
SNP on nucleotide 6815: A>T on the 5´end of the IGF2 gene (GenBank accession no.: L15440) 
Gaunt et al. (2001) Significant lower BMI values in TT homozygotes 
SNP - single nucleotide polymorphism, UTR - untranslated region 
In a sample of more than 1,000 Caucasian men, AA homozygotes of the IGF2 ApaI 
(rs689) polymorphism had a significant lower body weight as well as significant higher 
serum IGF2 levels (O'Dell et al., 1997). The conclusion drawn by the authors favours a 
better glucose utilisation by AA homozygotes of the IGF2 ApaI (rs689) polymorphism that 
explains the lower body weight (O'Dell et al., 1997). 
The same results were assessed by Sayer, Syddall, O'Dell, Chen, Briggs, Briggs, Day & 
Cooper (2002) who studied more than 700 men and women from Hertfordshire. Higher 
IGF2 serum levels were found in individuals homozygotic for the A-allele of the IGF2 ApaI 
(rs689) polymorphism. However, only a non-significant association could be found for 
genotype, body height and weight to be higher in GG homozygotic men of the IGF2 ApaI 
(rs689) polymorphism. In women, the trend was vice versa. No impact of the ApaI 
genotype (rs680) was found on adult grip strength.  
Gaunt et al. (2001) searched for gene variants in the IGF2 gene locus that may influence 
the BMI of more than 2,700 men of the Northwick Park Heart Study II. Eleven SNPs on 
different loci of the IGF2 gene were selected for analysis but only four of them had an 
impact on the BMI. Homozygotes of the rare ApaI A-allele (rs680) had significant lower 
BMI values than heterozygotes and GG homozygotes. Lower BMI values were also 
observed in carriers of the variant allele (TT and GG, respectively) of SNPs 6815A/T and 
1926C/G. The 1156T/C polymorphism had an inverse effect: carriers of the variant allele 
(CC) had higher BMI values than homozygotes of the ancestral T-allele (Gaunt et al., 
2001).  
Higher grip strength levels following different measurement protocols were documented in 
women homozygotic for the G-allele of the IGF2 ApaI (rs689) polymorphism in 
comparison to AA women (Schrager et al., 2004). Homozygotic women for the A-allele 
had also significant lower FFM than heterozygotes or GG homozygotes. Contrary, no 
significant genotype effects were found in men (Schrager et al., 2004).  
In 156 men and women of three-quarter Caucasian origin, genotype effects on strength 
loss, muscle soroness, and increases in circulating levels of creatine kinase and 
myoglobin concentration after muscle-damaging eccentric exercise were examined 
(Devaney et al., 2007). All assessed parameters described muscle damage after bounds 
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of eccentric exercise. Seven SNPs of the IGF2 gene were selected for comparison: 
rs2230949 (C16646T in the 3´-UTR), rs3213221 (C13790G in the 1st intron), rs3213220 
(T13705C in the 1st intron), rs3213216 (G12655A in the 1st intron), rs4244808 (A1364C in 
the 1st intron), rs7924316 (G11711T in the 3-Downstream region), and rs680 (G17200A, 
ApaI, in the 3´-UTR). All analyzed SNPs in the IGF2 gene except the IGF2 rs3213216 
polymorphism had an impact on muscle damage at least in a subgroup. In GG 
homozygotic men for the C13790G SNP (rs3213221) immediate postexercise strength 
losses, soroness 3 days postexercise, and serum creatine kinase activity 7 days 
postexercise were greater than in individuals carrying other genotypes. The same was 
observed in men homozygotic for the A-allele of the ApaI SNP (rs680). For men 
heterozygotic for the C16646T polymorphism (rs2230949) muscle soroness 4 days after 
exercise was significantly lower than in men homozygotic for the C-allele. Only one 
subject (0,6%) was homozygotic for the rare T-allele (rs2230949). The same effects could 
not be determined in women whereas the impact of the T13705C polymorphism 
(rs3213221) on study parameter was significant only in women: Baseline strength was 
higher in heterozygotes; homozygotes of the rare C-allele were not found in the study 
population. Further, myoglobin and creatine kinase activity were significantly higher 4 
days postexercise in heterozygotic women than in TT homozygotes. Homozygotic men 
(GG and TT) for the G11711T polymorphism (rs7924316) showed greater strength loss 
and greater muscle soroness after exercise than heterozygotes. In men carrying the wild-
type genotype (GG) of the G11711T polymorphism (rs7924316) posterexercise myoglobin 
and creatine kinase activity was higher than in heterozygotes. Summing up, results affirm 
the thesis, that people may be differently predisposed to susceptibility to excessive 
exercise. Variants in the IGF2 gene seem to be of major impact (Devaney et al., 2007). 
2.1.3 Myostatin 
Myostatin is a negative growth factor belonging to the TGF-β family. Its synonym is growth 
and differentiation factor 8 (GDF8). It regulates muscle growth from embryogenesis to the 
development of mature adult tissue and it is nearly exclusively expressed in muscle 
tissue. An inhibition of the myostatin signalling transduction pathway leads to an increase 
of muscle mass (McPherron, Lawler & Lee, 1997; McNally, 2004). Interestingly, a loss of 
adipose tissue was found concomitant to increased muscle growth due to myostatin 
inhibition (McPherron et al., 1997; McNally, 2004; Rodgers & Garikipati, 2008).  
Myostatin is synthesized and secreted in its inactive preform. After dimerisation myostatin 
is re-cleaved and binds to the TGF-β receptor activating the Smad signalling pathway that 
is regulatory in gene expression. Follistatin can inhibit myostatin by binding the latent 
myostatin form as there are also other myostatin binding proteins known (Rodgers & 
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Garikipati, 2008). The overexpression of myostatin evidently causes loss of muscle mass 
and function (McPherron et al., 1997; McNally, 2004). The role of myostatin in muscle 
mass regulation should always be considered together with other regulatory factors of 
muscle growth like IGF1 (McNally, 2004; Rodgers & Garikipati, 2008). Insuline like growth 
factors are considered to be antagonists of myostatin (see chapter 2.1.2.2) and muscle 
fiber size is maintained due to the balance of these positive and negative growth 
regulators (Lalani, Bhasin, Byhower, Tarnuzzer, Grant, Shen, Asa, Ezzat & Gonzalez-
Cadavid, 2000). 
Analyses of the myostatin mRNA levels of the soleus and gastrocnemius muscles of 
weight-bearing and hindlimb unloading mice indicate actions of myostatin different to that 
of a negative regulator of muscle growth (Carlson, Booth & Gordon, 1999). Higher 
myostatin mRNA levels were found only in the gastrocnemius before significant muscle 
atrophy occurred. The gastrocnemius muscle is predominately composed of type II 
muscle fibers. No elevated myostatin mRNA levels could be detected in the soleus, which 
has a high percentage of type I muscle fibers and showed greater muscle atrophy due to 
hindlimb unloading. Furthermore, analyses revealed the highest myostatin levels in 
muscles with the greatest fiber cross sectional area contradicting the theory that myostatin 
is a negative regulator of muscle growth. The authors conclude that under normal 
physiological conditions myostatin does not regulate fiber size because of its presence in 
muscles with the highest fiber cross sectional areas (Carlson et al., 1999), whereas in 
myostatin knockout mice muscle hypertrophy is seen (McNally, 2004; Rodgers & 
Garikipati, 2008). Myostatin is discussed to be involved in the reinforcement of a fast 
muscle phenotype because it may be able to downregulate the expression of slow type I 
fiber proteins and therefore is indirectly responsible for muscle fiber size. Further, 
myostatin may act as a negative regulator of satellite cell proliferation in fast skeletal 
muscles, which could explain high amounts of myostation mRNA in muscles with high 
fiber cross sectional areas (Carlson et al., 1999). However, Gonzalez-Cadavid, Taylor, 
Yarasheski, Sinha-Hikim, Ma, Ezzat, Shen, Lalani, Asa, Mamita, Nair, Arver & Bhasin 
(1998) did not find any differences concerning myostatin immunostaining neither in type I 
nor type II muscle fibers. 
Myostatin inhibition due to genetic variants, drugs, or specific inhibitors are considered to 
promote performance due to higher muscle mass and therefore better strength 
performance (McNally, 2004; Matsakas & Diel, 2005; Walsh, Metter, Ferrucci & Roth, 
2007). In a study examining long-term effects of myostatin inhibition, myostatin null mice 
had enhanced markers of regeneration and were more resistant to acute and chronic 
injuries than controls (Wagner, Liu, Chang & Allen, 2005). In HIV-patients with a decrease 
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in muscle mass higer myostatin levels were documented (Gonzalez-Cadavid et al., 1998). 
In persons with decreased pituitary activity, growth hormone treatment increased lean 
body mass. Concomitant a down-regulation of myostatin was observed as well as a better 
aerobic performance, which could be due to the higher muscle mass. According to these 
results, anabolic effects of growth hormone might be at least partly mediated by 
decreased myostatin levels (Liu, Thomas, Asa, Gonzalez-Cadavid, Bhasin & Ezzat, 
2003). 
2.1.3.1 Single nucleotide polymorphism K153R (rs1805086) 
A loss of function mutation in the myostatin gene is considered to cause increased muscle 
mass. Summing up all described mutations in the myostatin gene, eight polymorphisms 
(Saunders, Good, Lawrence, Ferrell, Li & Nachman, 2006) have been detected in the first 
two of the three exons of the myostatin gene. Most of them do not cause any amino acid 
exchange or are not common in the screened populations (Ferrell, Conte, Lawrence, 
Roth, Hagberg & Hurley, 1999; Seibert, Xue, Fried & Walston, 2001). The most promising 
polymorphism (rs1805086) is a switch from the nucleotide adenine to guanine in position 
153 on exon 2 causing the exchange of lysine by arginine in the myostatin protein. The 
K153R polymorphism in the myostatin gene was found more often in African-Americans 
than in Caucasians (Ferrell et al., 1999; Seibert et al., 2001). A comparison of the genetic 
variants in the myostatin gene between high responders and non-responders of different 
athlete status did not reveal any significant relationship between muscle mass increase 
after strength training and heritability. However, none of the responders was homozygotic 
for the less frequent R153 allele with the amino acid arginine present, whereas three of 
the nonresponders were R153 homozygotes (100% of RR homozygotes) of the African-
Americans (Ferrell et al., 1999). 
The influence of the K153R polymorphism on strength was aimed to be assessed in a 
training study with young men (Thomis, Huygens, Heuninckx, Chagnon, Maes, 
Claessens, Vlietinck, Bouchard & Beunen, 2004). The hypothesis was that with the 
presence of the R153 allele, initial strength levels were lower but strength gain due to 
heavy resistance strength training was higher. The hypothesis could not be approved 
because only one of the 57 volunteers was homozygotic for the R153 variant. The 
frequency of the K153R polymorphism was lower in the used population than described 
elsewhere (Ferrell et al., 1999). All subjects were twin pairs (Thomis et al., 2004).  
Participants of the Women´s Health and Aging Study II were genotyped for the K153R 
polymorphism and results were correlated with strength measurements of the grip, hip, 
and knee flexors (Seibert et al., 2001). Higher strength levels were seen in participants 
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carrying the KK genotype in comparison to RR homozygotes and heterozygotes. The rare 
RR genotype was only found in African-Americans but not in Caucasians (Seibert et al., 
2001). A comparison of the impact of the myostatin genotype on the flexor strength in 
different joints revealed that the hip flexion was affected the most. As the major hip flexor 
is the iliopsoas which is primarly composed of type I muscle fibers, authors conclude an 
influence of the myostatin gene variant predominantly on type I muscle fibers (Seibert et 
al., 2001). This is contradictory to the results of myostatin mRNA levels in different muscle 
types described in mice by Carlson et al. (1999). 
32 volunteers of different age and sex participated in a 9 week one-leg strength training 
program for the knee extensor and agreed in genotyping their K153R gene variant (Ivey, 
Roth, Ferrell, Tracy, Lemmer, Hurlbut, Martel, Siegel, Fozard, Jeffrey Metter, Fleg & 
Hurley, 2000). Among these participants, no man carrying the rare R-allele was present, 
whereas five of the 14 women were heterozygous. Differences in muscle volume increase 
after strength training were not statistically significant, but there was a tendency that 
heterozygotes had a greater pretraining muscle mass and a higher increase in muscle 
mass due to strength training. The trend in the muscle mass increase after training was 
maintained when the baseline muscle volume was covaried in the analysis (Ivey et al., 
2000). Results indicate an influence of the K153R myostatin polymorphism on muscle 
mass response to training but suggestions are limited due to the small sample size. 
Besides these findings gender differences concerning the frequency of the rare R-allele 
were noted with a higher incidence in women (Ivey et al., 2000). Outcomes disagree with 
those of Seibert et al. (2001) and Carlson et al. (1999) because in their analyses the R-
allele was linked to weaker phenotypes or to less training response. On the other hand 
results affirm the hypothesis of Thomis et al. (2004). 
Roth, Martel, Ferrell, Metter, Hurley and Rogers (2003) found a decreasing myostatin 
expression in 15 subjects completing the same heavy resistance strength training as 
previously described. The higher initial myostatin levels (2 weeks before strength training) 
were the greater was myostatin expression decrease (48 to 72 hours after strength 
training). Neither gender nor age differences could be observed. No genotypes of the 
participants were available (Roth et al., 2003).  
In comparison of the selected gene variants linked to endurance performance in nine 
excellent cross-country runners including one world champion, the KK genotype was 
interpreted as the more favouring one. Six of the nine runners were homozygotic for this 
variant (Gonzalez-Freire et al., 2008). Authors did not discuss to very low frequency of the 
R-allele, which may cover advantegous effects of it on endurance performance. 
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Between excellent lightweight rowers, professional road cyclists, Olympic-class runners, 
and non-athletic controls no differences were found in the frequency of the myostatin gene 
variant (Muniesa et al., 2008). 
Summing up published data there is no clear evidence whether the KK or the RR 
genotype is more favourable for performance. Training studies are even contradicting 
concerning whether the expression of myostatin increases or decreases after resistance 
training  (Willoughby, 2004; Raue, Slivka, Jemiolo, Hollon & Trappe, 2006).  
On the other hand, there are further links that the myostatin as a negative growth 
regulator has an impact on performance because performance phenotypes are affected 
by other polymorphisms, even in other species, especially when the variant causes as 
loss-of-function mutation: Lee (2007) showed that the increase in muscle mass results in 
better running speed and sprint performance in dogs. Furthermore, there is a positive 
correlation between racing grade and myostatin deficiency mutation in dogs (Mosher, 
Quignon, Bustamante, Sutter, Mellersh, Parker & Ostrander, 2007). There is evidence that 
myostatin inhibition correlates with athletic performance which is also supported by a boy 
carrying a myostatin nonsense mutation and having unusual strength for his age. His 
mother, heterozygotic for the same mutation, was a professional sprinter (McNally, 2004; 
Lee, 2007; Mosher et al., 2007).  
2.2 Alpine skiracing 
Alpine skiracing is a complex sport and therefore it is difficult to decide, which specific 
ability is crucial for success in alpine skiing. Certainly, the skiing technique as well as the 
skis have a high influence on skiing performance at high levels (Jeschke, Lorenz, 
Filadoro, Tusker, Grosser & Weinbuch, 1994). Nevertheless, physiological and metabolic 
aspects play at least a minor role in success in skiing competition (Axtell, Rinehardt, Finn, 
Stofan, Martens, Kenefick & Pier, 1997; Bosco, 1997). During 1990 and 2000 researchers 
and sport scientists tried to highlight the importance of different physiological and 
metabolic conditions concerning skiing performance, whereas afterwards studies focused 
increasingly on technical and biomechanical aspects. 
In 1983, Brown and Wilkinson (1983) compared VO2max of national, devisional and club 
skiers. They could not find any differences in the VO2max that would allow distinguishing 
between the different skiing classes but strength, power and anaerobic fitness outcomes 
were higher in national skiers. Results indicate that aerobic fitness is not determining for 
success in skiing competition but it is supposed that anaerobic fitness, strength and power 
measurements are adequate for distinguishing between different classes of ski-racers 
(Brown & Wilkinson, 1983).  
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Following Andersen and Montgomery (1988), the aerobic demands in alipine skiracing 
account for up to 90-95% but the high VO2max levels in elite skiers may rather reflect their 
training program than the physiological demands of the competition. In fact, a high 
glycogen utilisation seems to be necessary due to the impeded blood flow and the 
therefore impaired oxygen delivery during the race (Andersen & Montgomery, 1988).  
Assessed VO2max levels in competitive alpine skiracers were 52.9 ± 6.8 ml/kg body 
weight/min (Stanek, von Duvillard & LeMura, 1997), and 55 ± 3.5 ml/kg body weight/min 
(females) and 60 ± 4.7 ml/kg body weight/min (males) (Neumayr, Hoertnagl, Pfister, 
Koller, Eibl & Raas, 2003). Whereas athletes of other complex sport disciplines as for 
example material arts, ball games, and hepathlon, have compareable VO2max values 
(about 50 - 60 ml/kg body weight/min), endurance athletes (e.g. runners, rowers, cyclists, 
cors-country skiers) averagely have higher ones (about 65 - 70 ml/kg body weight/min) 
(de Marees, 2002). Unfortunately, assessed VO2max values in alpine skiers were not 
devided into the subcategories slalom, giant slalom and downhill (Stanek et al., 1997; 
Neumayr et al., 2003).  
Due to this described impeded blood flow during the skiing competition, Axtell et al. (1997) 
support the thesis that aerobic fitness is co-determining for success. Analysing 
cardiorespiratory and metabolic characteristics of junior athletes of the United States´ ski 
team it was found that aerobic as well as anaerobic capacities were highly developed. Leg 
strength and power are equally important because highly developed leg strength allows 
the muscle to perform at submaximal effort during downhill passages. The submaximal 
function results in an increased blood flow indicating a higher percentage of aerobic 
energy supply and avoids the accumulation of anaerobic by-products and strenuous 
fatigue. In summary, this thesis indicates that although anaerobic capacities are crucial for 
success in competition, a highly developed aerobic system is likewise necessary for rapid 
regeneration when lactid acid accumulates. Both metabolic pathways therefore seem to 
act symbiotically (Axtell et al., 1997).  
Steadman, Swanson, Atkins and Hagerman (1987) even state, that aerobic fitness is 
more important than anaerobic conditioning in alpine skiers because strength and power 
during the race can only be maintained with a high functional aerobic system. Findings of 
decreasing oxygen uptake during the alpine skiing season are contrary (Haymes & 
Dickinson, 1980). Decreasing VO2max levels assessed on a cycle ergometer test may 
reflect the importance for muscular endurance capacity in alpine skiracing. As muscular 
endurance capacity is co-responsible for competition performance, it may develop during 
the skiing season whereas aerobic capacity is higher at the beginning of the season due 
to pre-seasoning aerobic fitness training (Haymes & Dickinson, 1980). 
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Using cycling ergometer protocols in alpine skiers for testing physiological characteristics 
are discussed contradictory because they determine general fitness levels but not specific 
motor demands (White & Johnson, 1991; Baum, Hoy, Leyk & Essfeld, 1997). Although 
heart rates, VO2max and lactate measurements can be helpful in the training process and 
validation of alpine skiers, in laboratory tests incremental exercise protocols should be 
used because they better reflect race demands (White & Johnson, 1991; Hartmann, 
Mader, Babiel, Spitzenpfeil & Mester, 1997; Reid, Johnson, Kipp, Albert & White, 1997). 
The use of incremental protocols instead of long duration all-out tests is supported by 
results of Baum et al. (1997). The comparison of sport students not familiar with alpine 
skiing and D-kader alpine skiers revealed no differences. As ski races last between 45 
seconds and 2 minutes, tests for correlation analysis with performance in competition 
should also lie within this period (Bacharach & von Duvillard, 1995). Even the use of the 
Wingate test, which is an exercise protocol of maximal cycling against a given resistance 
calculated on the basis of body weight for 30, 60, 90, or 120 seconds could not highlight 
any correlation between test outputs and the national USSA points representing skiing 
performance (Petelin von Duvillard & Knowles, 1997). However, the Wingate test caused 
a better correlation than the box jump test or the vertical jump test did (Petelin von 
Duvillard & Knowles, 1997). Similar outcomes are described by Reid et al. (1997) who 
correlated the results of a test battery including High Box Jumping, Hexagonal Obstacle, 
Single Leg Lateral Vault and Two Leg Lateral Vault test with skiing classes. Although 
there were partly significant different test outcomes between four different skiing classes, 
the test battery was not able to distinguish between all four levels (Reid et al., 1997).  
The same test battery was used by Klika and Malina (1997) in combination with 
antropometric measurements to predict skiing performance in youth. In females, weight, 
vertical jump performance and high box jumping performance predicted national skiing 
points (similar to FIS points) with a determination coefficient of 0.52. In males, age, high 
box jumping performance and skinfold thickness turned out to be relevant for success with 
a determination coefficient of 0.31 (Klika & Malina, 1997).  
Although some tests were able to partly predict skiing performance (Klika & Malina, 1997), 
none of them could include skiing technique which is undisputable a main factor for 
success in alpine ski races. Nevertheless, physiological properties are likewise important 
because they allow realising technical demands (Bosco, 1997). A crucial physiological 
skill for success in competition is speed endurance. As during ski races the leg extensor 
acts in strech-shortening-cycles, the muscular activity is similar as in jumps. 
Improvements of speed endurance (continuous jumping) also improved characteristics of 
explosive power outputs suggesting that especially fast twitch muscle fibers represent the 
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physiological background of success in skiing competition. Subjects rich in fast twitch 
fibers are also favoured in their anaerobic capacity.  
As speed endurance was proposed as the most predictable parameter for success in 
skiing competition (White & Johnson, 1991; Bosco, 1997), two training theories emerged 
(Steadman et al., 1987): either strength training and jumping enhances speed endurance 
or speed endurance is improved on the basis of a highly developed aerobic metabolic 
pathway. Bosco et al. (1997) favored strength and jumping training to improve speed 
endurance because speed endurance turned out to depend on explosive power and 
relative explosive strength and not on maximal dynamic strength. As there exists a 
positive relationship between explosive strength and testosterone levels, strength training 
is an important training tool to increase testosterone levels whereas aerobic endurance 
training can even inhibit testosterone production due to a stimulated release of beta-
endorphine. Testosterone can even favour the switch of fast twitch muscle fibers to a 
more glycolitic profile (Bosco, 1997). Concordantly, Frick, Schmidtbleicher, Raschner and 
Müller (1997) recommend continuous jumps for slalom training because they stimulate the 
sport-specific stretch-shortening cycles in knee and hip extensors.  
Whereas most analyses did not differ between various skiing disciplines, a comparison of 
German ski racers in 1990 highlighted differences between specialists (Jeschke et al., 
1994). Whereas for slalom and giant slalom strength endurance turned out to be the most 
determining physiological skill, in downhill and super G races the percentage of fast twitch 
muscle fibers determines performance. In slalom and giant slalom dynamic strength and 
aerobic endurance as parts of strength endurance are important because of the high 
frequency of rhythmic changes. In downhill and super G the ability to build and endure 
high levels of lactate is crucial which is a characteristic of fast twitch glycolytic fibers. 
Nevertheless, aerobic endurance also has an impact on success but not in the same 
extent as it has in slalom races. Authors conclude, that endurance capacity is more 
important to ski racing competition performance than strength parameters are (Jeschke et 
al., 1994). Similar outcomes are assessed in longitudinal studies of the Austrian Ski Team 
between 1997 and 2000 (Neumayr et al., 2003). Success in skiing competition is based 
on many physiological variables with aerobic power and muscle strength as the two main 
determining factors (Neumayr et al., 2003).  
Apart from all these theories, alpine skiers were assigned to the power athlete group 
concerning the ACTN3 R577X genotype in an genetic study of Russian athletes and 
controls (Druzhevskaya et al., 2008). 
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3 Materials and methods 
3.1 Subjects 
The study was approved by the ethic committee of the University of Medicine of Vienna 
and of the general hospital of Vienna (AKH). All participants gave written informed 
consent for saliva sample collection, the DNA extraction and the allelic discrimination in 
over 20 gene loci (see Appendix) before analysis. Only five polymorphisms are part of 
this analysis, whereas the remaining ones are assessed within other parts of the whole 
gene project. Participants were informed advised of their rights and risks and all 
samples were coded and not registered with the names of the participants. Anonymous 
sample guaranteed the highest data security for participants. 
Table 3: Exclusion criteria for athletes 
- Proven intake of performance-enhancing substances (WADA) 
- Existance of coronary heart diseases 
- Existance of chronic diseases 
- Existance of a manifest diabetes mellitus type I (insulin-dependent) or type II. A 
manifest type II diabetes mellitus is given if fasting blood glucose levels are 
higher than 126 mg/dl and there appear typical symptoms as polyurie and thurst 
at two different days or fasting blood glucose levels are higher than 126 mg/dl 
and not-fasting blood glucose exceeds 200 mg/dl at two different days. 
Table 4: Inclusion criteria for sedentary controls 
- Good health status 
- No existance of a manifest diabetes mellitus type I (insulin-dependent) or type II.  
- No known coronary heart diseases or other chronical disorders 
- A maximum of three hours of exercise or exhausting leisure time per week (for 
sedentary controls) 
- no professional sport engagement but more than three hours of exercise or 
exhausting leisure time per week (for active controls) 
- At least 18 years old 
Alltogether 244 volunteers donated saliva samples and were genotyped for the five 
selected polymorphisms. 40 of them met inclusion criteria for one of the athlete groups 
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(see Appendix, Table 3). Control subjects had to meet the inclusion criteria listed in 
Table 4. They were recruited via a public notice on the Austrian Institute for Sports 
Medicine (Österreichisches Institut für Sportmedizin) in Vienna, Auf der Schmelz 6 (see 
Appendix). The group consisted of 204 sedentary and moderate active volunteers 
(Table 5). 
Originally, the high-performance athlete group should consist of the national team as 
well as the A, B, and C-kader of the Austrian ski federation. Because Austria is one of 
the top nations in the international ski circuit, it can be assumed that selected athletes 
are of the world´s best. Unfortunately, the Austrian national ski team has not been 
available yet, but athletes of other sports (athlete group inclusion criteria for athlete 
groups are listed in the Appendix - Written informed consent), mostly runners, agreed 
in collaboration (Table 5). Runners and road cylists were group together as endurance 
athletes. Athletes of other disciplines (not endurance-dominated) are analysed in other 
parts of the whole gene project. Runners (800 meters to marathon running) had to 
have a personal best in at least one discipline that corresponds more than 800 points 
following the IAAF Scoring Table3. Road cylists had to be participants of international 
competitions of the Union Cylcist Internationale and to be a member of a professional 
road cyling team.  
Table 5: Study population subcategories 
Sedentary (<3 hours exersice/week) 87 subjects 
Active (>3 hours exercise/week) 117 subjects 
Athletics - middle and long distance run 38 subjects 
Road cycling 2 subjects 
Characteristics of the study cohorts (sedentary, active, athletes) are shown in Table 6. 
26 of the 40 endurance athletes had already finished their carrer when they donated 
their saliva sample, whereas the remaining 14 were still active. Retired athletes filled 
out the athlete’s questionnaire (chapter 3.2.2) and referred the answers to their active 
period. 
 
                                                   
3
 The IAAF (International Association of Athletics Federation) Scoring Table was developed in 
1982 and is yearly updated. According to statistical methods, each performance is assigned a 
certain score. The IAAG Scoring Table allows interdisciplinary comparisons because the same 
score corresponds to the same performance even in different disciplines. 
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Table 6: Characteristics of study cohorts 
N = 244 
Sedentary (<3 hours 
exersice/week) 
n = 87 
Active (>3 hours 
exercise/week) 
n = 117 
Athletes 
(endurance) 
n = 40 
% female (n) 61% (53) 47% (55) 3% (12) 
Age [years] 39.6 ± 15.38 (20-
77) 
34.2 ± 15.96 (19-
70) 
32.13 ± 11.58 (18-
67) 
BMI [kg/m²] 24.3 ± 5.25 (17.9-
45.7) 
22.9 ± 2.69 (17.3-
31.3) 
20.98 ± 2.18 (17.1-
25.6) 
PAL 
1.68 ± 0.30 (1.27-
2.77) 
1.87 ± 0.37 (1.13-
2.9) 
2.28 ± 0,21 (1.14-
2.88) 
Values are expressed as mean ± standard devision, minimum and maximum is given in braces 
3.2 Physical activity questionnaires 
Both, athletes and sedentaries were asked to fill out a questionnaire assessing 
personal data, the amount of training and other training details and weekly physical 
activity, respectively.  
3.2.1 Physical activity questionnaire for sedentary controls 
Sedentaries were asked to fill out the Physical Activity Frequency Questionaire (PAFQ; 
see Appendix) to assess their weekly physical activity including work, leisure time and 
mileage.  
The evaluation of PAFQ offers the energy expenditure per day, which also reflects 
physical activity when it is corrected for age, sex and body height and weight.  
The questionnaire was validated previously using a heart rate monitor over 3 days 
(Bernstein, Sloutskis, Kumanyika, Sparti, Schutz & Morabia, 1998); group activities 
were chosen on the basis of 24 hours recalls4 and calculated referring to the Joint 
FAO/WHO/UNU Expert Committee on Energy and Protein Requirements (1985).  
                                                   
4
 24 hours recall: A person is asked about his or her eating habits in the last 24 hours without 
announcement. The nutrient intake is calculated with the use of the nutritional information panel 
(Elmadfa, 2004, p. 52).   
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3.2.1.1 PAFQ computing 
With the PAFQ, the overall activities of one week can be assessed. If the total amount 
of hours is different from 168, a two step correction has to be made (Bernstein et al., 
1998). First, the total sleep time is set to 45:30 hours if it is less or to 70 hours if it is 
more. Second, the total duration for non-sleep activities is calculated and 
proportionately adjusted so that the sum of sleep and non-sleep time yields 168 hours. 
All corrections were calculated using Microsoft Excel® 2003. 
The energy expenditure is computed by multiplication of the time spent for activities 
with multiples of the basal metabolic rate. Multiplication factors were used according to 
Ainsworth, Haskell, Whitt, Irwin, Swartz, Strath, O'Brien, Bassett, Schmitz, 
Emplaincourt, Jacobs & Leon (2000) except activity levels for the leisure time activities, 
and sitting which refer to the the Joint FAO/WHO/UNU Expert Committee on Energy 
and Protein Requirements (1985). The basal metabolic rate is calculated with the help 
of personal data as follows: men: basal metabolic rate = 1 kcal/hour x body weight; 
women: 0,9 kcal/hour x body weight (Elmadfa, 2004). The energy expenditure depends 
on sex, age, body height, and other factors whereas the Physical Activity Level (PAL) is 
independent from these variables. The PAL can be calculated by dividing the energy 
expenditure per day by the basal metabolic rate (Elmadfa, 2004).  
The part “sports – detailed information” is not included in the original validated 
questionnaire, but it was included to collect some qualitative information on sport 
activities carried out by controls.  
3.2.2 Physical activity questionnaire for athletes 
The PAFQ was not used for athletes because it does not reflect an athlete´s lifestyle. 
To allow a comparison of the PAL of sedentaries and athletes, the PAL of athletes was 
set at 2.3 which reflects routine training and can be sustained for extended periods of 
time (Shetty, 2005).  
The questionnaire for athletes assessed besides personal data training details as main 
disciplines, amounts of training in hours and kilometers per week, age of access into 
competitioning and the personal appreciation of the importance of either strength or 
endurance for success in competition (see Appendix). 
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3.3 Determination of genetic variants 
3.3.1 Pretests to compare DNA sample collection and isolation 
protocols 
Table 7: Overview of compared methods for DNA isolation 
Sample collection protocoll Medium Isolation protocoll 
Take blood sample Venous blood (EDTA) PeqLab Blood DNA Isolation 
Kit  
Biozym Buccal Brushes Saliva Epicentre® Buccal AmpTM 
DNA Extraction Kit 
Biozym Buccal Brushes Saliva Gentra® Purgene® Buccal 
Cell Kit  
Mouthwash (Listerine®) Saliva Gentra® Purgene® Buccal 
Cell Kit 
OrageneTM Self Collection Kit Saliva Ethanol extraction 
OrageneTM Self Collection Kit Saliva Gentra® Purgene® Buccal 
Cell Kit 
To find a preferably cheap, fast and for the probands an as easy as possible method 
for DNA collection as well as an efficient protocol to isolate DNA of sufficient amount 
and pureness, different methods were compared prior to the start of sample collection 
(Table 7).   
3.3.1.1 DNA Isolation using PeqLab Blood DNA Isolation Kit 
3.3.1.1.1 Sample collection 
Venous blood was collected by a physician in a tube containing EDTA as 
anticoagluant. Three participants volunteered as donators. Two of them were male; 
one was female. 
3.3.1.1.2 DNA isolation 
For DNA isolation, the peqGOLD Blood DNA mini Kit (Safety-Line, atricle number 12-
3482-xx) from PeqLab, Biotechnology GmbH, Erlangen, Germany, was used.  
Lysis: 500 µl blood, 50 µl OB Protease, 500 µl BL Buffer and 5 µl RNase were mixed, 
afterwards incubated for 10 minutes at 70° C. 
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Ligation: Lysate was mixed with 520 µl isopropanol and 650 µl of the mixture were 
transferred to the HiBind DNA-column in a 2 ml centrifuge tube. Tube was centrifuged 
for 1 minute at 8000 xg and flow-through was wasted. Procedure was repeated three 
times to load and ligate the whole lysate-isopropanol mixture on the column. 
Wash: Column was transferred to a new 2 ml centrifuge tube und loaded with 600 µl 
DNA-Wash Buffer, afterwards centrifuged for 1 minute at 8000 xg. Flow-through was 
discarded. This step was repeated twice without changing the tube. After the wash, the 
column was centrifuged at maximum speed for 2 minutes to ensure complete dryness. 
Eluation: Column was transferred to a new 2 ml centrifuge tube and loaded with 100 µl 
Eluation Buffer that had previously been heated to 70° C. Column was incubated at 
room temperature for 2 miuntes, afterwards centrifuged for 1 minute at 8000 xg. 
Eluation step was repeated a second time, afterwards column was wasted. 
Quantification: Absorption of the undiluted eluat was measured at 230, 260, 280 and 
320 nm using a Biophotometer. Isolated amount of DNA was calculated by 
mulitiplication the absorption at 260 nm with 50 (extinktion for DNA); quality was 
evaluated using the ratio of the absorption at 260 and 280 nm, which should be higher 
than 1.7. Furthermore, there should be a distinct peak to see at the absorption of 260 
nm.  
Results: The obtained amount of DNA out of 500µl blood was somewhat lower than the 
expected one given by the supplier (5.6 – 8.4 µg). The quality of the obtained DNA 
indicated by the absorption ratio at 260 and 280 nm and a distinct peak at 260nm was 
satisfactory; see Table 8:  and Figure 2. 
Table 8: Absorption, concentration and amount of isolated DNA from venous blood using 
peqGOLD Blood DNA mini Kit 
 
Absorption at λ [nm]: 
 
Sample 230 260 280 320 DNA [ng/µl] 
Ratio 
260/280 
Isolated amount 
[µg] 
1 0.055 0.355 0.165 0.029 17.75 2.2 3.55 
2 0.095 0.443 0.218 0.029 22.15 2.0 4.43 
3 0.013 0.211 0.09 0.019 10.55 2.3 2.11 
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Figure 2: Spectra of absorption with maximum peak at 260 nm 
3.3.1.2 Saliva sample collection using sterile buccal brushes 
3.3.1.2.1 Sample collection 
Saliva samples were collected from three volunteers using sterile buccal brushes 
(Catch-AllTM Sample Collection Swabs,  article number QEC091H) from Epicentre® Bio 
Technologies, Biocym Scientific GmbH, Biocym Biotech Trading GmbH, Vienna, 
Austria. Brushes were rotated against the left, the right, or both cheeks for 20 times, 
airdryed, afterwards closed with the original hard-pack plastic carrier. Volunteers were 
asked not to drink, eat or smoke one hour before sample collection.  
3.3.1.2.2 DNA Isolation using Buccal AmpTM DNA Extraction Kit 
DNA was isolated using QuickExtract™ DNA Extraction Solution from Epicentre® Bio 
Technologies, Biocym Scientific GmbH, Biocym Biotech Trading GmbH, Vienna, 
Austria (article number QE09050). 
The kit contained a single tube-system. Buccal brushes were rotated in the precast 
extraction solution for 10 times and pressed against the side while removing them. 
Solution was mixed using a vortex and incubated for 1 minute at 65° C, followed by a 
period of 2 minutes and 98° C.  
Quanitification: Quality evaluation and quantification was measured using a Jenway 
6305 Spectrophotometer. Unfortunately, absoprtion measurements were not 
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successful, probably due to a very low DNA concentration or poor DNA quality. The 
supplier does not recommend absorption measurement to ascertain DNA concentration 
but because alternative methods had not been exercised in our laboratory, absoprtion 
measurement was the method of choice. 
3.3.1.2.3 DNA Isolation using Gentra® Purgene® Buccal Cell Kit 
DNA was isolated from saliva samples collected by sterile buccal brushes (see 
3.3.1.1.1) using Gentra® Puregene® Buccal Cell Kit from Qiagen, Hilden, Germany 
(article number 158845). 
Cell Lysis: Collection brush was removed from the handle using sterile scissors and 
was placed in a 1.5 ml centrifuge tube containing 300 µl Cell Lysis Solution. After 
addition of 1.5 µl Proteinase K, sample was incubated for 1 hour at 55° C. 
RNase treatment: 1.5 µl RNase A was added to the lysate and sample was incubated 
for 15 minutes at 37° C. 
Protein Precipitation: Sample was cooled on ice for 1 minute. After addition of 100 µl 
Protein Precipitation Solution, sample was again placed on ice for 5 minutes. Sample 
was centrifuged for 3 minutes at 13,000 xg and 24° C to form a tight protein pellet. 
DNA Precipitation: Supernantant was transferred to a 1.5 ml centrifuge tube containing 
300 µl Isopropanol and 0.5 µl Glycogen Solution. Sample was mixed and incubated for 
at least 5 minutes at room temperature. Sample was centrifuged for 5 minutes at 
13,000 xg and 24° C. Supernantant was discharged; tube was dried using absoption 
paper. After addition of 300 µl ethanol, sample was centrifuged for 1 minute at 13,000 
xg and 24° C. Ethanol was discharged and tube was opend in the laminar flow for 10 
minutes to airdry. 
DNA Hydration: To re-hydrate DNA, 15 µl Hydration Solution were added and sample 
was allowed to stand overnight at room temperature.  
Quantification: Sample was diluted 1:50 using Hydration Solution. Absorption was 
measured at 230, 260, 280 and 320 nm using a Biophotometer. Isolated amount of 
DNA was calculated by mulitiplication the absorption at 260 nm with 50 (factor for 
DNA); quality was evaluated using the ratio of the absorption at 260 and 280 nm and 
the characteristics of the absoprtion spectra. 
Results: Obtained DNA ranged from 0.2 µg to 4.12 µg, whereas the obtained amount 
differed between volunteers and was compareable within controls from the same 
Material and methods 
 34 
donator. DNA quality was unsatisfactory as the ratio of the absorption at 260 and 280 
nm, which should be greater than 1.7, was just about one. Additionally, there was no 
clear peak to observe at 260 nm.  
3.3.1.3 Saliva sample collection using OrageneTM Self Collection Kit 
3.3.1.3.1 Sample collection 
Saliva samples were collected via mouthwash using OrageneTM Self Collection Kit, Vial 
Format OG 100, DNA Gentotek Inc., Kanata, Ontario, Canada. OrageneTM Self 
Collection Kit is an all-in-one system for DNA collection, preservation, transportation 
and purification of DNA from saliva. Volunteers salivated into the prepared collecting 
tube for saliva until it was filled up to the given mark. Volunteers were asked not to 
drink, eat or smoke one hour before sample collection. After gentle shaking, sample 
was aliquoted to 250 µl. 
3.3.1.3.2 DNA purification (Ethanol extraction) 
Sample incubated for 1 hour and 50° C. After addition of 10 µl DNA Purifier, sample 
was placed on ice for 10 minutes. Sample was centrifuged at 15,000 xg and 24° C for 5 
minutes; supernantant was transferred to a new centrifuge tube. After addition of 2.5 µl 
glycogen solution and 250 µl 95-100% ethanol, sample was incubated for 10 minutes 
at room temperature, afterwards centrifuged at 15,000 xg and 24° C for 2 minutes. 
Supernantant was discharged carefully without loosing the pellet and tube was dried 
using absorbent paper. 125 µl 70% ethanol were added and sample was incubated for 
1 minute at room temperature. Afterwards ethanol was discharged and tube was dried 
again. After addition of 50 µl DNA Buffer, sample was incubated at room temperature 
for two days to ensure rehydration of DNA. 
Addition of glycogen solution and the ethanol wash step were optional and the protocol 
was done with and without those two steps.  
Quantification: Absorption was measured at 230, 260, 280 and 320 nm using a 
Biophotometer. Isolated amount of DNA was calculated by mulitiplication of the 
absorption at 260 nm with 50 (factor for DNA); quality was evaluated using the ratio of 
the absorption at 260 and 280 nm and the characteristics of the absorption spectra. 
Results: DNA was concentrated between 4.0 µg/ml and 8.7 µg/ml, whereas obtained 
amount differed between volunteers and was compareable within controls from the 
same donator. Absolute DNA yields ranged from 1.6 up to 3.48 µg, which is distinctly 
less than the expected amount given by the supplier with 110 µg. DNA quality was 
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unsatisfactory but problems during the protein precipitation step may be responsible for 
poor ratios of the absorption at 260 nm and 280 nm (<1.7). There were no appreciable 
differences in the result wether the optional glycogen addition and the optional ethanol 
wash were done or not.  
3.3.1.3.3 DNA Isolation using Gentra® Purgene® Buccal Cell Kit 
After gentle shaking, sample (saliva mixed with OrageneTM Self Collection Kit) was 
aliquoted to 250 µl in 1.5 ml centrifuge tubes and incubated for 1 hour and 50° C. 
Cell Lysis: 62.5 µl Cell Lysis Solution and 1.66 µl RNase A Solution were added and 
sample was incubated for 10 minutes at room temperature.  
Protein Precipitation: After addition of 104.4 µl Protein Precipitation Solution, sample 
was centrifuged for 5 minutes at 15,000 xg and 24° C to form a tight protein pellet. 
DNA Precipitation: Supernantant was transferred to a 1.5 ml centrifuge tube containing 
313 µl Isopropanol and 2.5 µl Glycogen Solution. Sample was mixed and centrifuged 
for 3 minutes at 2,000 xg and 24° C. Supernantant was discharged; tube was dried 
using absorbent paper. After addition of 312.5 µl 70% Ethanol, sample was centrifuged 
for 1 minute at 2,000 xg and 24° C. Ethanol was discharged and tube was opend in the 
laminar flow for at least 10 minutes to airdry. 
DNA Hydration: To re-hydrate DNA, 25 µl Hydration Solution were added and sample 
was allowed to stand overnight at room temperature.  
Quantification: Sample was diluted 1:50 using Hydration Solution. Absorption was 
measured at 230, 260, 280 and 320 nm using a Biophotometer. Isolated amount of 
DNA was calculated by mulitiplying the absorption at 260 nm with 50 (factor for DNA); 
quality was evaluated using the ratio of the absorption at 260 and 280 nm and the 
absorption spectra. 
Results: DNA was concentrated between 4.3 µg/ml and 10.7 µg/ml, whereas obtained 
DNA amounts differed between volunteers and they were compareable within controls 
from the same donator. Absolute DNA yields ranged from 0.86 µg up to 2.14 µg, which 
is distinctly less than the expected amount, and the necessary amount, respectively. 
DNA quality was slightly impaired because the ratio of the absorption at 260 and 280 
nm, which should be greater than 1.7, was somewhat lower (1.4 – 1.6).  
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3.3.1.4 Sampe collection via mouthwash and DNA isolation using the Gentra® 
Purgene® test kit 
3.3.1.4.1 Sample collection 
Saliva was collected using a mouthwash protocol. Participants were asked not to eat, 
drink or smoke the hour before sample collection. They swished 10ml Listerine® 
mouthwash for at least 20 seconds throughout the mouth and expectorated into a 50 
ml centrifuge tube.  
3.3.1.4.2 DNA Isolation using Gentra® Purgene® Buccal Cell Kit 
DNA was extracted from saliva samples using Gentra® Purgene® Buccal Cell Core Kit 
A with the following protocol. Chemicals used are listed in Table 9. 
Lysis: Collected samples were centrifuged for 10 minutes with 2,000 xg at 25° C using 
a Hettich Rotina 450R centrifuge. The step was repeated if the pellet was loose after 
centrifugation, otherwise, supernatant was wasted and 1.1 ml Cell Lysis Solution were 
added. After inverting the tube 50 times, samples were incubated at room temperature 
for 15 minutes during gentle shaking (80 rpm on Elmi shaker DOS-20L).  
Table 9: Chemicals necessary for DNA isolation 
Reagent Supplier Article number 
Cell Lysis Solution Qiagen Sciences 158906 
DNA Hydration Solution Qiagen Sciences 158918 
Ethanol for molecular biology 99.8% Merck 1.08543.0250 
Glycogen Solution 20mg/ml Qiagen Sciences 158930 
2-Propanol for molecular biology ≥99% Sigma I9516 
Protein Precipitation Solution Qiagen Sciences 158910 
Purgene Proteinase K Qiagen Sciences 158918 
RNase A Solution Qiagen Sciences 158922 
Sterile water for irrigation Laboratoire Aguettant  
Protein Precipitation: From the whole lysate, 500 µl were transfered to 2 ml 
microcentrifuge tubes in each case. Each sample was extracted in doubles. 5 µl 
Proteinase K were added, tubes were inverted three times and mixed virgously on a 
vortex for 20 seconds. After incubation at room temperature for 10 minutes, 5 µl RNAse 
A were added, tubes were inverted 25 times and incubated for 15 minutes at 37° C 
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using a HLC heating block. 170 µl protein precipitation solution were added, samples 
were mixed virgously on a vortex and placed on crushed ice for 10 minutes. Afterwards 
samples were centrifuged for 10 minutes at 10,000 xg at 4° C using a Hereaus Fresco 
17 microcentrifuge.  
DNA Precipitation: Supernatant was transvered to a new 2 ml microcentrifuge tube 
containing 500µl Isopropanol and 2.5 µl glycogen solution. After inverting the tubes for 
50 times, they were again centrifuged for 4 minutes at 3,000 xg and 20° C using the 
Hettich Rotina 450R centrifuge. Supernatant was wasted and tubes were dried using 
absorbent paper (Kimtech Science- Precision Wipes). The pellet was washed with 70% 
ethanol (7:3 ethanol: sterile water, v/v) and centrifuged at 300 xg for 4 minutes. Again, 
supernatant was wasted and tubes were dried using absorbent paper. Samples were 
allowed to stand open for 1 minute in the laminar flow (Steril Polaris) to make sure that 
the whole solvent was removed.  
DNA Hydration: The DNA pellet was re-hydrated in 200 µl Hydration Solution. After 1 
hour at 65° C in the HLC heating block, samples were allowed to stand overnight on a 
shaker at 80 rpm (Elmi DOS-20L).  
Quantification: Afterwards the final DNA concentration and the absorbation ration of 
260 nm to 280 nm allowing quality control were measured using the Nanodrop 1000 
Spectrophotometer from PeqLab Biotechnologies. Samples were stored in 50 µl 
aliquots at -20° C. 
Results: DNA was concentrated between 10 µg/ml and 300 µg/ml, whereas obtained 
DNA amounts differed between volunteers and they were compareable within controls 
from the same donator. Absolute DNA yields ranged from 4 µg up to 120 µg. DNA 
quality was slightly impaired because the ratio of the absorption at 260 and 280 nm, 
which should be greater than 1.7, was somewhat lower (1.4 – 1.6).  
3.3.1.5 Evaluation of the tested methods for DNA isolation 
Sample collection from saliva was preferred, because the obtained DNA quality and 
amount was satisfactory for further analyses. Further, saliva collection is a non-invasive 
method and therefore more comfortable for participants and no doctor is needed as he 
or she were for blood collection. In fact, participants are able to collect the sample on 
their own with a short description of the collection process.  
Table 10 gives on overview on the obtained DNA amounts, the obtained DNA quality 
and the costs for the analyses of each tested method. 
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Table 10: Overview on compared methods for DNA collection and isolation 
Method: Collection and isolation 
DNA amount 
[absolute; 
µg] 
DNA quality 
[Absoprtion: 
260/280nm] 
Price/sample 
[€] 
Take blood sample 
(venous EDTA blood) 
PeqLab Blood DNA 
Isolation Kit 
2.11 – 4.43  2.0 – 2.3 2.28 
Biozym Buccal 
Brushes (saliva) 
Epicentre® Buccal 
AmpTM DNA 
Extraction Kit 
Absoprtion measurements 
were not successful; 
quantification and quality 
evaluation not possible 
3.79 
Biozym Buccal 
Brushes (saliva) 
Gentra® Purgene® 
Buccal Cell Kit 
0.2 – 4.12 << 1.7  4.15 
Mouthwash using 
Listerine® (saliva) 
Gentra® Purgene® 
Buccal Cell Kit 
4.0 – 120.0 1.4 – 1.6 2.23 
OrageneTM Self 
Collection Kit (saliva) 
Gentra® Purgene® 
Buccal Cell Kit 
0.86 -2.14 1.4 – 1.6 24.82 
OrageneTM Self 
Collection Kit (saliva) Ethanol extraction 1.6 – 3.48 
<< 1.7 
(improveable) 23.88 
Although the OrageneTM Self Collection Kit offers a comfortable collection and 
isolation possibility, the Gentra® Purgene® Buccal Cell Kit in combination with a 
mouthwash protocol for sample collection was preferred. It can be assumed, that the 
quality of DNA offered using the OrageneTM Self Collection Kit could be improved 
eliminating initial problems in the purification step but the kit itself was expensive for all 
participants regarding the costs per samples. As the isolation protocol was 
compareable regarding the time and difficulty, the cheaper variant was chosen which 
was the sample collection using mouthwash combined with DNA isolation using 
Gentra® Purgene® Buccal Cell Kit. Although the DNA quality was not completely 
satisfactory, the allelic discrimination could be determined without any problems, 
therefore absorption ratios (260/280nm) of 1.4 – 1.6 were accepted.  
The other methods did not offer a DNA quality that was high enough for further 
analyses (PCR) or the obtained amount of the DNA was simple too little because in the 
whole study project, over 20 polymorphisms were planned to be genotyped. That 
requires a miniumum of absoult DNA amount higher than 1.5 µg. 
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3.3.2 Determination of allelic distribution using polymerase chain 
reaction 
Single nucleotide polymorphisms (SNP) are variants of a single nucleic acid sequence. 
The allelic discrimination assay is an end-poibt assay, which means that data is 
collected at the end of the Polymerase Chain Reaction (PCR) process. It assay allows 
the genotyping of two possible variants in a target template sample (the gene locus 
carrying the polymorphism). The method distinguishes between homozygotes (carriers 
of two identical alleles, of either a couple of allele 1 or a couple of allele 2) and 
heterozygotes (carriers of both alleles). The quality of the target DNA sequence cannot 
be determined with the applied method.  
In the allelic discrimination assay for each sample, there is a unique pair of fluorescent 
dye detectors. Each fluorescent dye detector perfectly matches one of the two alleles 
(Figure 3). The changes in fluorescence of the dyes associated with the probes are 
measured at the end of the allelic discrimination run after the signal was amplified due 
to repeated polymerisation cycles: In an initial step, the DNA double helix (DNA 
template = sample) is separated. The forward- and reverse primer5 (assay 
components) can bind to each single strand and enable the DNA polymerase6 (assay 
component; yellow symbol in Figure 3) to bind and synthesis the complementary 
strand. This procedure is repeated and the DNA template proliferates, which at least 
causes the amplification of the fluorescent signal. Probes7 (assay components) 
carrying one of the two fluorescent dye detectors (V: VIC® dye fluorenscence; F: 
FAMTM dye fluorencence; Figure 3) can bind to the replicated DNA single strands – the 
VIC® dye fluorenscence detector only matches allele 1, the FAMTM dye fluorencence 
only matches allele 2. Only after perfect match the the fluorenscence dye detector is 
quenched (Q: Quencher; assay component; Figure 3) and after repeated 
polymerisation cyles the changes in the both fluorencence signals are recorded. 
Increases in the VIC® dye fluorescence only indicate homozygosity for allele 1, 
increases in the FAMTM dye fluorescence only indicate homozygosity for allele 2, and 
increases in both fluorescence signlas indicate heterozygosity (AppliedBiosystems, 
2006). 
                                                   
5
 Primer: Short RNA strand that enables DNA polymarases to bind to the DNA single strand; 
“forward” and “reverse” describes the concordance to either one or the other single strand. After 
cleavage of the DNA double helix two complementary single strands exist (Loeffler, 2001) 
6
 DNA polymerase: Enzyme that synthesizes a DNA single strand to a double strand; the 
generated double strand can serve as new template after afresh cleavage. (Loeffler, 2001) 
7
 Probe: Short RNA strand that habours the polymorphism to be analysed (AppliedBiosystems, 
2006) 
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Figure 3: Matches and mismatches between target and probe sequences in the TaqMan® 
Gene Expression Assays (Livak, Marmaro & Todd, 1995; in AppliedBiosystems, 2006, p. 3) 
The analysed gene polymorphisms are listed in Table 11. 
Table 11: Overview on analysed gene polymorphisms 
 Gene variant 
Database 
SNP (rs#) Base pair exchange/SNP type Test kit 
ACTN3 R577X rs1815739 
C to T transition substitution/ 
nonsense mutation 
Applied Biosystems 
C_590093_1_ 
IGF1 AG rs35767 G to A transition substitution 
Applied Biosystems 
C_799146_10 
INS-IGF2 CG/ 
C13790G 
rs3213221 C to G transversion substitution 
Applied Biosystems 
C_3145635_10 
INS-IGF2 GT rs7924316 G to T transversion subtitution 
Applied Biosystems 
C_29192859_10 
MSTN K153R rs1805086 
C to T transition substitution/ 
missense mutation 
Applied Biosystems 
C_282184_30 
3.3.2.1 Pretest to assess suitable DNA concentration for optimal test conditions 
For PCR run conditions, supplier recommend to use 1-20 ng DNA per well. To find out 
the optimal amount of DNA applied, all kits were tested with the use of 20, 10, 5, and 1 
ng DNA per well. The lowest amount of DNA was chosen, which showed a signal that 
was at least twice as high as the negative control (NTC), or had a comparable high 
signal as higher concentrations. DNA solutions were prepared as described in chapter 
3.3.2.2, PCR run and evaluation of results are described in chapter 3.3.2.3 and 3.3.2.4.  
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Table 12: Results of a concentration test  
Well Sample Name Signal Allele X  Signal Allele Y  Call 
A1 NTC 0,563 0,619 NTC 
A2 NTC 0,548 0,56 NTC 
A3 NTC 0,546 0,55 NTC 
A4 20ng DNA/well 2,241 2,092 Both 
A5 20ng DNA/well 2,201 2,048 Both 
A6 10ng DNA/well 2,087 1,962 Both 
A7 10ng DNA/well 2,072 1,941 Both 
A8 5ng DNA/well 2,018 1,889 Both 
A9 5ng DNA/well 2,027 1,878 Both 
A10 1ng DNA/well 1,712 1,679 Both 
A11 1ng DNA/well 1,829 1,745 Both 
B1 20ng DNA/well 2,711 0,654 IGF2 rs3213221C 
B2 20ng DNA/well 2,732 0,657 IGF2 rs3213221C 
B3 10ng DNA/well 2,687 0,644 IGF2 rs3213221C 
B4 10ng DNA/well 2,68 0,648 IGF2 rs3213221C 
B5 5ng DNA/well 2,586 0,618 IGF2 rs3213221C 
B6 5ng DNA/well 2,602 0,618 IGF2 rs3213221C 
B7 1ng DNA/well 2,344 0,598 IGF2 rs3213221C 
B8 1ng DNA/well 2,368 0,608 IGF2 rs3213221C 
B9 20ng DNA/well 2,237 2,134 Both 
B10 20ng DNA/well 2,252 2,104 Both 
B11 10ng DNA/well 2,218 2,032 Both 
B12 10ng DNA/well 2,238 2,065 Both 
C1 5ng DNA/well 2,095 2,08 Both 
C2 5ng DNA/well 2,16 2,015 Both 
C3 1ng DNA/well 1,891 1,816 Both 
C4 1ng DNA/well 1,824 1,812 Both 
C5 20ng DNA/well 2,195 1,972 Both 
C6 20ng DNA/well 2,178 1,998 Both 
C7 10ng DNA/well 2,104 1,986 Both 
C8 10ng DNA/well 2,105 2,013 Both 
C9 5ng DNA/well 2,104 1,868 Both 
C10 5ng DNA/well 2,128 1,868 Both 
C11 1ng DNA/well 1,824 1,655 Both 
C12 1ng DNA/well 1,692 1,742 Both 
Table 12 shows the results of the concentration test with primer for the IGF2 CG 
polymorphism. 5 ng DNA per well were the chosen DNA amount for this assay 
because with 1 ng DNA per well the signal was clearly weaker and higher 
concentrations did not cause much higher signals.  
 
 
 
Table 13 shows the used DNA concentrations per well for each applied assay. 
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Table 13: Suitable amounts of DNA per well for each applied assay 
Polymorphism Used DNA concentration for PCR 
ACTN3 R577X  (rs1815739) 1 ng DNA per well = 0.09 ng/µl 
IGF1 AG (rs35767) 10 ng DNA per well = 0.89 ng/µl 
IGF2 CG (rs3213221) 1 ng DNA per well = 0.09 ng/µl 
IGF2 GT (rs7924316) 5 ng DNA per well = 0.44 ng/µl 
MSTN K153R (rs1805086) 5 ng DNA per well = 0.44 ng/µl 
One well contains 11,25µl 
3.3.2.2 Test Preparations 
The sample concentration was measured using the Nanodrop 1000 Spectrophotometer 
from PeqLab Biotechnologies and diluted with sterile water to a concentration of 0.89 
ng/µl following the calculation shown in Figure 4. If the necessary sample amount to 
prepare 100µl of the diluted solution was lower than 1 µl, a multiple greater than 1 µl 
and the corresponding amount of water were used. If the original DNA concentration 
was higher than 180 ng/µl, an intermediate solution concentrated to 8.9 ng/µl was 
prepared and diluted 1:10 (v/v). The 0.89 ng/µl concentrate was diluted 1:2 (v/v) to 0.44 
ng/µl, which was afterwards diluted 1:5 (v/v) to reach the 0.09 ng/µl solution. Figure 4 
also gives three examples to clarify the calculation and dilution steps. 
Formula:  
100 µl 0.89ng/µl dilution = (c [original solution] *100)/0.89 µl original solution + 1 - (c [original 
solution] *100)/0.89 µl sterile water 
Example 1: csample= 54.2 µg/ml = 54.2 ng/µl; necessary amount: 100 µl (for PCR and further 
dilutions) 
54.2 ng … 1 µl 
0.89 ng … x, x = 0.89 / 54.2 = 0.016; 0.016 * 100 (100 µl dilution are necessary) = 1.64  1.64 
µl sample + 98.36 µl (100-1.64) sterile water  dilution concentrated 0.89 ng/µl 
0.44 ng/µl dilution: 50 µl dilution concentrated 0.89 ng/µl + 50 µl sterile water 
0.09 ng/µl dilution:14 µl dilution concentrated 0.44 ng/µl + 56 µl sterile water 
Example 2: csample = 95 µg/ml = 95 ng/µl; necessary amount: 100 µl (for PCR and further 
dilutions) 
95 ng … 1 µl 
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0.89 ng … x, x = 0.89 / 95 = 0.009; 0.009 * 100 (100 µl dilution are necessary) = 0.9  0.9 µl 
sample amount is too little for pipetting  150 µl dilution are prepared: 1.41 µl + 148.59 µl 
sterile water  dilution concentrated 0.89 ng/µl 
0.44 ng/µl dilution: 50 µl dilution concentrated 0.89 ng/µl + 50 µl sterile water 
0.09 ng/µl dilution:14 µl dilution concentrated 0.44 ng/µl + 56 µl sterile water 
Example 3: csample = 290.9 µg/ml = 290.9 ng/µl; necessary amount: 100 µl (for PCR and further 
dilutions) 
290.9 ng … 1 µl 
0.89 ng … x, x = 0.89 / 290.9 = 0.003; 0.003 * 100 (100 µl dilution are necessary) = 0.3  0.3 µl 
sample amount is too little for pipetting and the necessary amount of water is with over 150 µl 
too much for addition  an intermediate solution concentrated 8.9 ng/µl was prepared:  
Dilution concentrated 8.9 ng/µl: 1.22 (0.3*4, so the amount for pipetting is higher than 1) + 38.78 
ng/µl sterile water (for 40µl dilution) 
0.089 ng/µl dilution: 10 µl dilution concentrated 8.9 ng/µl + 90 µl sterile water 
0.44 ng/µl dilution: 50 µl dilution concentrated 0.89 ng/µl + 50 µl sterile water 
0.09 ng/µl dilution:14 µl dilution concentrated 0.44 ng/µl + 56 µl sterile water 
Figure 4: Formula for preparing a sample dilution concentrated 0.89 ng/µl 
The assay reagent was prepared light protected. 12.5 µl TaqMan® Genotyping Master 
Mix (Applied Biosystems, P/N: 4371355, L/N: 0811030) was mixed with 0.625 µl TE 
buffer (Hydration Solution; see Table 9) and 0.625 µl Genotyping Assay 40X (see 
Table 11) per well. The necessary amount of Master Mix was calculated by multiplying 
the mentioned amounts of components with the planned number of wells on the 
reaction plate and adding extra reactions to provide excess volume for the loss that 
occurs during reagent transfer (AppliedBiosystems, 2006).  
3.3.2.3 Polymerase Chain Reaction 
For allelic discrimination, a Real-Time PCR System (Applied Bisystems 7500) was 
used. Samples were pipetted on a 96-well plate, each well containing 13.75 µl assay 
reagent and 11.25 µl sample. For the negative control (NTC), sterile water was used.  
Allelic discrimination of each polymorphism and sample was determined in triplets. 
After pipetting, the reaction plate was covered with optical adhesive cover and the plate 
was centrifuged briefly to eliminate air blowing. After loading the reaction plate intp the 
PCR system, the Pre-Read Run was followed by the amplification period. The assay 
finished with the Post-Read Run (Figure 5 - Figure 7). Assay conditions were assessed 
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using the corresponding software to the PCR system follwing the suppliers quidance 
step by step (AppliedBiosystems, 2006). 
 
Figure 5: Design of an allelic discrimination assay 
 
 
Figure 6: Assay conditions of the PCR Pre-Read and Post-Read Run 
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Figure 7: Assay conditions of the PCR amplification run 
During the Pre- and Post-Read Run, samples were once heated to 60° C. The 
amplification run started with a ramp to 95° C that were maintained for 10 minutes. 
Afterwards 40 repeats of 15 minutes at 92° C followed by one minute at 60° C. 
Whereas the Pre- and Post-Read Run measured the fluorescence of the two dye 
detectors (VIC® and FAMTM), during the amplification run the DNA stretch that 
harbors the polymorphism of interest was replicated in repeated cylcles. As either the 
VIC® or the FAMTM detector (homozygotes) or both detectors (heterozygotes) 
increased due to the quenching process after a successful match on the DNA stretch 
that harbors the adequate allele variant, the change in fluorescence between the Pre- 
and Post-Read Run allowed the discrimination of the genotype (AppliedBiosystems, 
2006, see also chapter 3.3.2). 
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3.3.2.4 Evaluation of results 
DNA stretches carrying the polymorphism of interest were labeled with two different 
dyes (VIC® and FAMTM), one for the ancestral allele and one for the variant. Results 
were interpreted manually according to the given NTC (Figure 8). In samples 
homozygote for allele 1, only the fluorescent signal of the VIC® dye detector increased, 
resulting in a x-value at least twice as high as the x-value of the NTC. In samples 
homozygote for allele 2, only the fluorescent signal of the FAMTM dye detector 
increased, resulting in a y-value at least twice as high as the y-value of the NTC. 
Samples that were different from the NTC according to the x- as well as the y-value 
(fluorescence of the VIC® and FAMTM dye detector increased) were outlined as 
heterozygotes (AppliedBiosystems, 2006, see Figure 8).  
 
Figure 8: Interpreted results of the PCR Post-Read Run 
3.4 Statistical analysis 
For all statistical analyses, SPSS for Windows® Version 15.0 was used. Normal 
distribution was tested using the Kolgomorov-Smirnov-Test as well as the histogram 
and the QQ-Plot. Group differences between the cohorts “controls - athletes” were 
tested using the Student´s t-test and the Mann-Whitney U-test, respectively. 
Differences between sedentaries, active people and endurance athletes as well as 
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gender differences were tested using crosstabulation (Pearon´s Chi-Scare). 
Alternatively, the study population was devided into quartiles using the PAL value. The 
three cohorts of different activity level (first quartile, second and third quartile, fourth 
quartile) were compared using crosstabulation (Pearon´s Chi-Scare). The significance 
level α was set 0.05.  
3.4.1 Test for Hardy-Weinberg Equilibrium 
Genotype distribution was compared with Hardy-Weinberg equilibrium using Pearson 
Chi-Scare Goodness-of-fit Test and Exact Test (Ryckman & Williams, 2008). Expected 
genotype distribution was calculated using the formula p² + 2pq + q² = 1, whereas q 
and p were the expected allele frequencies (Ryckman & Williams, 2008). Expected 
minor allele frequencies were given by the kit supplier, the dominant allele frequency 
was calculated using the formula q = 1 – q ([p+q] ² = 1).  
The reference population consisted of 45 Caucasians except for the myostatin 
polymorphism, which refers to 19 Caucasians (AppliedBiosystems, 2009a; b; f; e; c; d). 
Minor allele frequencies and expected genotype distributions are listed in Table 14. 
Table 14: Minor allele frequencies used for the calculation of the Hardy-Weinberg 
equilibrium 
Calculated genotype distribution 
p² + 2pq + q² = 1 
Polymorphism 
AB minor allele and 
minor allele 
frequency (n=45 
Caucasians) 
*AGI minor allele 
frequency (n=19 
Caucasians) 
p²: 
freuquency 
of the 
homozygote 
variant 
genotype 
2pq: 
freuquency 
of the 
heterozygote 
genotype 
q²: 
freuquency 
of the 
homozygote 
ancestral 
genotype 
ACTN3 R577X (rs1815739) T: 0.36 0.130 0.461 0.410 
IGF1 (rs35767) A: 0.13 0.017 0.226 0.757 
INS-IGF2 (rs3213221) C: 0.47 0.221 0.498 0.281 
INS-IGF2 (rs7924316) T: 0.46 0.212 0.497 0.292 
MSTN K153R (rs1805086) C: 0.03* 0.001 0.058 0.941 
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4 Results and discussion 
4.1 Study population 
Alltogether 244 volunteers were genotyped for the above-described polymorphisms. 40 
of them met inclusion criteria for one of the athlete groups (see Appendix, Table 5, p. 
27). The residual 204 control subjects were grouped to sedentary and active 
subcategories (Table 5, p. 27). Gender distribution, age, BMI and PAL of the three 
study cohorts are described in Table 6 on page 28. 
The whole study group was not in Hardy-Weinberg equilibrium for tested 
polymorphisms ACTN3 R577X (rs1815739), MSTN K153R (rs1805086), IGF2 
(rs3213221) and IGF1 (rs35767). For the IGF2 (rs7924316) polymorphism, the 
population was in Hardy-Weinberg equilibrium. When the study population was devided 
into control subjects and endurance athletes, results were the same except for the 
ACTN3 R577X (rs1815739) polymorphism: whereas control subjects were not in Hary-
Weinberg equilibrium, the athlete group was. Results of the Exact Test and the Person 
Chi-Scare Goodness-of-fit Test were identical, although the Exact Test is 
recommended (Ryckman & Williams, 2008) for small sample sizes as in our analysis.  
Several reasons, for example genotyping errors, might cause genotype distributions 
different from Hardy-Weinberg equilibrium (Ryckman & Williams, 2008). In our 
analyses, interpreting the absence of Hardy-Weinberg equilibrium must be done with 
caution because several assumptions must be met for the derivation of the Hardy-
Weinberg theorem (Ryckman & Williams, 2008). Some of them might not be fulfilled in 
our case: firstly, the population size might be not large enough, especially in the athlete 
cohort. In fact, it is extremely difficult to get an athlete sample, which is large and even 
“pure” enough. There is hardly a large athlete cohort engaged on a professional and 
excellent level in one sport discipline, which would be necessary for significant 
genotype distribution testing. Other analyses are limited by similar problems (Ivey et 
al., 2000; Thomis et al., 2004; Muniesa et al., 2008).  
In the original study protocol, the Austrian national ski team was planned to be 
genotyped. The idea of analysing the nation ski team was that Austria is one of the 
most successful countries in the international ski circuit and a rather large sample 
cohort might have been possible. Unfortunately, the Austrian Ski Association (ÖSV) 
has not yet agreed in cooperation.  
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Although our sample size, especially in the athlete group, was small, the reference 
population for Hardy-Weinberg testing was as well (n = 45).  
Another assumption for the derivation of the Hardy-Weinberg equilibrium theorem is 
that there are no fitness differences among genotypes (Ryckman & Williams, 2008). As 
accurately, fitness differences among genotypes are our hypothesis, significant 
differences of the genotype distribution to Hardy-Weinberg equilibrium could be a link 
for the genotype influence on fitness phenotypes, even though we might not be able to 
detect genotype differences in our sample cohorts of different activity level. Naturally, 
the deviation form Hardy-Weinberg Equilibrium is an insufficient evidence for the 
impact of a polymorphism on fitness parameters. 
In fact, testing Hardy-Weinberg Equilibrium using Person Chi-Scare Goodness-of-fit 
test has several limitations and deviation form Hardy-Weinberg Equilibrium should be 
interpreted with caution (Goddard, Ziegler & Wellek, 2009).  
4.2 Differences between cohorts of different activity level 
Table 15: Genotype distribution in controls and athletes 
Polymorphism and 
ancestral allele Cohort 
Homozygote 
ancestral 
genotype 
(females/n) 
Heterozygote 
genotype 
(females/n) 
Homozygote 
variant 
genotype 
(females/n) 
Sedentary 28% (15/22) 46% (22/36) 26% (8/20) 
Active 32% (14/35) 44% (24/48) 23% (11/25) 
ACTN3 R577X 
(rs1815739) 
Ancestral allele:      
R (C) Athletes 42% (11/15) 39% (9/14) 19% (4/7) 
Sedentary 72% (30/56) 26% (13/20) 3% (2/2) 
Active 70% (33/76) 28% (14/30) 2% (2/2) 
IGF1 (rs35767) 
Ancestral allele: A  
Athletes 78% (20/28) 19% (3/7) 3% (1/1) 
Sedentary 36% (15/28) 49% (21/38) 14% (8/11) 
Active 40% (16/43) 42% (22/45) 18% (11/19) 
IGF2 (rs3213221) 
Ancestral allele: G 
Athletes 47% (5/17) 47% (6/17) 6% (1/2) 
Sedentary 37% (19/29) 51% (22/40) 12% (4/9) 
Active 32% (14/34) 49% (25/52) 20% (10/21) 
IGF2 (rs7924316) 
Ancestral allele: T 
Athletes 31% (3/11) 53% (7/19) 17% (2/6) 
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Sedentary 96% (44/75) 4% (1/3)  - - - 
Active 99% (49/107) - - -  1% (0/1) 
MSTN K153R 
(rs1805086) 
Ancestral allele:      
K (C) Athletes 100% (12/36) - - - - - - 
Distributions of the genotypes of analysed polymorphisms are shown in Table 15. 
Determination of genotype was successful in 78 sedentary people, 108 active people 
and, 36 athletes, respectively. Group comparisons were performed on the one hand 
between sedentaries, active people and endurance athletes; on the other hand, the 
sample was devided into quartiles using the PAL value as parameter of physical 
activity as there were also some very active people with high PAL levels (>2.0).  
It has to be mentioned that in the original study protocol the Austrian ski team was 
aimed to be genotyped. Unfortunately, the ski team has not been available yet. As the 
hypothesis was, that polymorphisms linked with strength, power, and body composition 
phenotypes might influence success in skiing competition, the analysed polymorphisms 
were selected within that context. Effects of the selected genetic variants on endurance 
performance have not sufficiently been resolved, especially for the polymorphisms in 
the IGF1 (rs35767) and IGF2 (rs3213221 and rs7924316) genes. 
4.2.1 The α-actinin-3 R577X (rs1815739) polymorphism 
The R577X polymorphism is an allele change from CGA to TGA. Whereas CGA codes 
for arginine, TGA is a stop codon, the exchange results in a nonsense function of the 
ACTN3 protein (NCBI, 2009b).  
No significant differences (p>0.05) between cohorts (neither between quartiles nor 
between athletes and controls) of different activity level could be found concerning the 
distribution of the ACTN3 R577X genotype (Table 15, p. 49, Figure 9).  
Whereas many researches support that the ACTN3 RR genotype favours sprint and 
power performance (Yang et al., 2003; Druzhevskaya et al., 2008; Papadimitriou et al., 
2008), data is not that evident for the XX genotype and endurance performance. A 
higher frequency of the XX genotype in sample cohorts of endurance athletes in 
comparison to controls or sport-/power athletes suggested an advantage of the XX 
genotype for endurance performance (Yang et al., 2003; Niemi & Majamaa, 2005). The 
thesis was not confirmed in other endurance athlete samples (Lucia et al., 2006; 
Muniesa et al., 2008), some did even find an also higher occurrence of the RR 
genotype in elite endurance athletes (Yang et al., 2007; Ahmetov et al., 2008).  A 
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higher presence of the R-allele in endurance athletes might also refect requirements in 
modern endurance competitions: due to high running speeds and finial spurts, fast 
power generation is even important in endurance competitions (Lucia et al., 2006; 
Ahmetov et al., 2008). Additionally, it must be mentioned that only a higher frequency 
of XX homozygotes in endurance athletes compared with control subjects indicates a 
favourable role of the XX genotype. If a higher XX genotype was noticed in endurance 
athletes than in sprint or power athletes, that likely resulted of the higher RR genotype 
in the sprint/power cohort. The RR genotype is considered advantegous in complex 
sports, too. In Italian gymnasts the RR genotype was significanetly more frequent than 
in control subjects (Massidda, Vona & Calo, 2009). 
 
Figure 9: Mean PAL values in the ACTN3 R577X (rs1815739) genotype groups  
Results of the present investigation are to be assimilated to the number of negative 
outcomes. An explanation for diverging results was given by Eynon, Duarte, Oliveira, 
Sagiv, Yamin, Meckel and Goldhammer (2009). Genotyping of 155 Israeli athletes and 
240 sedentaries highlighted a higher frequency of the RR genotype in sprint athletes 
with a correlation between the RR genotype and success in sprint competition. The XX 
genotype was more often found in endurance athletes but frequency did not differ 
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between top-level and national runners. Authors conclude that the XX genotype might 
be additive to endurance performance but not critical whereas the RR genotype seems 
to be for sprint performance (Eynon et al., 2009). As the genotyping of East- and West-
African athletes (Yang et al., 2007) showed, the RR genotype may also be 
advantegous, at least not disadvantegous, for endurance performance.   
After splitting the control group into sedentary and active individuals, there was neither 
a difference concerning the ACTN3 R577X genotype distribution. Results agree with 
the thesis of Yang, Garton and North (2009), who concluded that the polymorphism 
contributes to the normal variations in muscle strength and sprinting speed, but it was 
not to be supossed to find differences within the control group. Delmonico, Zmuda, 
Taylor, Cauley, Harris, Manini, Schwartz, Li, Roth, Hurley, Bauer, Ferrell and Newman 
(2008) stated that there was an influence of the ACTN3 R577X polymorphism even in a 
non-athlete cohort, but the effect was only observable in a longitudinal design in older 
adults: in over 2000 older adults various parameters of muscle function were measured 
and associated with the ACTN3 polymorphism. Whereas there were no differences 
between genotype groups at baseline, the increase in the time spent for a 400-meter 
walk after 5 years was significantly higher in male XX homzygotes. Results indicate 
that the polymorphism might influence decline in physical performance in older adults 
but effects on performance were at most weak (Delmonico et al., 2008). No impact of 
the ACTN3 R577X variant concerning patterns of daily living was found in sedentary 
individuals (North et al., 1999). 
4.2.2 The IGF1 rs35767 polymorphism 
The selected polymorphism (rs35767) in the gene coding for IGF1 is a transition 
substitution of A by G in the nearGene-3 position with an unknown clinical association 
(AppliedBiosystems, 2009d; NCBI, 2009a).  
No significant differences (p>0.05) between cohorts (neither between quartiles nor 
between athletes and controls) of different activity level could be found concerning the 
distribution of the IGF1 rs35767 genotype (Table 15, p. 49, Figure 10).  
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Figure 10: Mean PAL values in the IGF1 (rs35767) genotype groups 
As IGF1 is a human growth factor, circulating IGF1 might have an impact on body 
composition and muscle growth (Sun et al., 1999; Yu & Rohan, 2000; Shyu et al., 
2005, and others. See also chapter 2.1.2). Therefore, polymorphisms that influence 
circulating IGF1 levels might also have an impact on strength phenotypes.  
We hypothesised that genotypes that increase IGF1 blood levels might occur in a 
higher frequency in alpine skiracers because they may support success in competition. 
Although strength and power-related phenotypes are important in endurance runners 
and cylists too (Lucia et al., 2006), escessive muscle growth might be disadvantegous. 
Therefore, it can be hypothesised that the variant in the IGF1 gene (rs35767) does not 
distinctly influence endurance performance.  
However, published data concerning the IGF1 rs35767 polymorphism is contradictory: 
The IGF1 rs35767 polymorphism did not show any correlation with circulating IGF1 
plasma levels in Caucasian women (Canzian et al., 2006) or with muscle regeneration 
after eccentric strength exercise in Caucasians (Devaney et al., 2007). Palles, 
Johnson, Coupland, Taylor, Carvajal, Holly, Fentiman, Silva Idos, Ashworth, Peto and 
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Fletcher (2008) highlighted an impact of the polymorphism on circulating IGF1 levels in 
middle-aged women. Lopez-Alarcon et al. (2007) found a moderate impact of the IGF2 
CT dinucleatide MS polymorphism on endurance performance (treadmill time and 
submaximal VO2 during stairclimbing and cycling) in sedentary premenopausal women 
of African-American and European-American origin. Carriers of the homozygote 189bp 
genotype showed higher endurance (time spent on treadmill during VO2max test) and 
better exercise economy (submaximal VO2 during stairclimbing and cycling). Within the 
HERITAGE Family Study (Sun et al., 1999), Caucasian sedentaries conducted an 
aerobic exercise training programm. In homozygotes for the 189bp allele of the IGF2 
CT dinucleatide MS polymorphism the gain in fatt free mass was significantely less 
than in subjects of the other genotype groups. However, the polymorphism did also 
influence baseline body composition (Sun et al., 1999). No results oo the impact of the 
IGF1 rs35767 polymoprhism on endurance performance could be found. 
4.2.3 The IGF2 rs3213221polymorphism 
The selected polymorphism (rs3213221) in the gene coding for IGF2 is a transversion 
substitution of C by G in the 1st intron of the gene with an unknown clinical association 
(Devaney et al., 2007; AppliedBiosystems, 2009e; NCBI, 2009d). 
No significant differences (p>0.05) between cohorts (neither between quartiles nor 
between athletes and controls) of different activity level could be found concerning the 
distribution of the IGF2 rs3213221 genotype (Table 15, p. 49, Figure 11).  
The impact of the genotype distribution on endurance performance has not been 
discussed in published data. Devaney et al. (2007) found differences between 
genotype groups in the response to eccentric strength training in the elbow flexor 
muscle only in men: Homozygotes of the rare allele (GG) showed greater strength 
losses (immediately after exercise), higher muscle soroness (3 days postexercise), and 
a higher creatine kinase activity as indicator for muscle damage ( 7 days postexercise) 
than homozygotes of the ancestral allele (CC). Mean values of the heterozygotes lied 
in the middle and were not significantly different to those of the homozygotes (Devaney 
et al., 2007).  
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Figure 11: Mean PAL values in the IGF2 (rs3213221) genotype groups 
Results of Devaney et al. (2007) indicate an association between the rare G-allele and 
muscle sensitivity to eccentric strength bounds. Present results did not reveal any 
differences concerning the IGF2 rs3213221 genotype and overall physical activity. 
Reasons might be that not the direct impact of a training input was assessed and 
secondly, the composition of the study cohorts, as only an endurance athlete group 
was used.  
4.2.4 The IGF2 rs7924316 polymorphism 
The selected polymorphism (rs7924316) in the gene coding for IGF2 is a transversion 
substitution of G by T in the intron (3-Downstream region, Devaney et al., 2007) of the 
gene with an unknown clinical association (AppliedBiosystems, 2009f; NCBI, 2009e). 
No significant differences (p>0.05) between cohorts (neither between quartiles nor 
between athletes and controls) of different activity level could be found concerning the 
distribution of the IGF2 rs7924316 genotype (Table 15, p. 49, Figure 12).  
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Figure 12: Mean PAL values in the IGF2 (rs7924316) genotype groups 
The IGF2 rs7924316 genotype distribution was the only one of the five analysed 
polymorphism that was in Hardy-Weinberg Equilibirum. As the assumption was made, 
that the remaining polymorphisms might have an influence on fitness phenotypes (see 
chapter 4.1) due to the absence of Hardy-Weinberg Equilibrium concerning the 
genotype distribution (Ryckman & Williams, 2008), this was not true fot the IGF2 
rs7924316 polymorphism. It can be speculated that the IGF2 rs7924316 polymorphism 
might not have any impact on the fitness phenotype. 
Devaney et al. (2007) found a link between differences in response to strength training 
and the IGF2 rs7924316 genotype, but only in men: Strength losses immediately after 
maximal isotonic eccentric strength exercise in the elbow flexor muscle were greater in 
homozygotic men of both variants (GG and TT) than in male heterozygotes. Effects 
lasted for 10 days. Muscle soroness 3 and 4 days posexersice was significantly higher 
in TT homozygotic men than in men carrying the other two genotypes. Myoglobin and 
creatine kinase activity was significantly higher in male TT homozygotes than in 
heterozygotic men indicating higher muscle damage in individuals carrying the TT 
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genotype. Mean value of the GG genotype was between but not significantly different 
to the other two genotype groups. The population studied consisted three-quarter of 
Caucasians and was in Hardy-Weinberg equilibrium for the IGF2 rs7924316 
polymorphism (Devaney et al., 2007). 
Findings of Devaney et al. (2007) indicate a higher sensitivity of individuals 
homozygotic for the IGF2 rs7924316 polymorphism to strength exercise in comparison 
to heterozygotes. Contradictory, in this analysis the overall activity level and not the 
effect of a special training input was examined and the athlete group consited of 
endurance athletes. Therefore, there is no analogism within the results. 
4.2.5 The myostatin K153R (rs18050586) polymorphism 
The K153R polymorphism is an allele change from AAG to AGG, which results in an 
amino acid exchange of lysine to arginine (NCBI, 2009c). Although both amino acids 
belong to the group of amino acids with charged and polar side chains (Loeffler, 2001), 
the exchange results in a missense function (NCBI, 2009c).  
No significant differences (p>0.05) between cohorts (neither between quartiles nor 
between athletes and controls) of different activity level could be found concerning the 
distribution of the MSTN K153R genotype (Table 15, p. 49, Figure 13).  
Interestingly, there were no athletes carrying the variant allele (Table 15, p. 49), 
whereas some of the controls did. In fact, the variant allele R of the MSTN K153R 
polymorphism is rather rare in Caucasians (minor allele frequency 0.03 (Applied 
Biosystems, 2009a)). Studies on the influence of the MSTN K153R polymorphism on 
physical performance in Caucasians failed, because there were no participants 
carrying the rare RR genotype (Ivey et al., 2000; Seibert et al., 2001; Thomis et al., 
2004). 
As the athlete cohort consisted of endurance specialists, the absence of a variant allele 
is not suprisingly. Various analyses found the KK genotype of the MSTN K153R 
polymorphism more advantageous for endurance performance (Gonzalez-Freire et al., 
2008; Muniesa et al., 2008; Ruiz, Gomez-Gallego, Santiago, Gonzalez-Freire, Verde, 
Foster & Lucia, 2009; Santiago, Ruiz, Muniesa, Gonzalez-Freire, Gomez-Gallego & 
Lucia, 2009). However, hypotheses, that the KK genotype favours endurance 
performance must be interpreted with caution: Although in world-class runners there 
were hardly athletes carrying the RR genotype (Gonzalez-Freire et al., 2008; Muniesa 
et al., 2008), this might be a consequence of the extreme low RR genotype frequency, 
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especially in the analysed Spain (Caucasian) sample. As the world´s best middle and 
long distance runners are mostly of African origin (Yang et al., 2007), the analyses of 
that ethnic group would be of interest. Ferrell et al. (1999) found a significant higher 
frequency of the rare RR genotype in African-Americans than in Caucasians. There 
might be similar differences between ethnic groups as they were found for the ACTN3 
R577X genotype. Whereas some analyses in Caucasian endurance athletes indicated 
a favourable role of the XX genotype for endurance performance (Yang et al., 2003; 
Niemi & Majamaa, 2005; Ahmetov et al., 2008),  the hypothesis could not be confirmed 
in a East and West African endurance runners. The XX genotype was hardly present, 
neither in the athlete nor in the control group (Yang et al., 2007). 
 
Figure 13: Mean PAL values in the MSTN K153R (rs1805086) genotype groups 
We had hypothesised that the MSTN K153R polymorphism might influence skiing 
performance as strength and endurance as well as partly body composition are 
important components for success. In elite soccer players (Juffer, Furrer, Gonzalez-
Freire, Santiago, Verde, Serratosa, Morate, Rubio, Martin, Ruiz, Arenas, Gomez-
Gallego & Lucia, 2009), there was no impact of the K153R polymorphism found on 
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success, nor was there a difference between the genotype frequency of male 
sedentaries, endurance athletes and soccer players (Juffer et al., 2009).  
4.3 Gender differences 
Neither in the whole study population nor within the three study cohorts (sedentary, 
active, athlete) gender differences could be detected (p>0.05). Although results were 
not significant, only female athletes carried the GG (variant) genotype in the IGF1 
(rs35767) gene (Table 15, p. 49). This is so much more demonstrative as only 3% (12 
individuals) of the athletes are female (Table 6, p. 28) whereas gender distribution was 
balanced in the sedentary and active control groups. Insignificance might be the 
consequence of the low number of subjects in the categories (36 endurance athletes 
are devided by sex and genotype).  
The impact of the IGF1 rs35767 and other polymorphisms (mainly in the IGF2 gene) on 
muscle generation after bouds of strength exercise was determined in Caucasian 
males and females (Devaney et al., 2007). There were no associations between 
muscle generation and the IGF1 rs35767 polymorphism and no gender differences 
could be observed. Considering all analysed polymorphisms (in the IGF1 and IGF2 
gene) there were more significant associations in men than in women but no apperant 
explanantion could be found (Devaney et al., 2007). A not significant trend for lower 
body height and relative mortality risk was observed only in female inhabitants of the 
Netherlands carrying the non-dominant (≠19) allele of the IGF1 CA dinucleotide 
microsatellite polymorphism (van Heemst et al., 2005). Other researches on genetic 
variants in the IGF1 gene included either only men or only women in their analyses 
(Jernstrom et al., 2001; Allen et al., 2002; Lopez-Alarcon et al., 2007) or did not find 
any gender differences (Rosen et al., 1998; Sun et al., 1999; Vaessen et al., 2001; 
Kostek et al., 2005; Morimoto et al., 2005; Canzian et al., 2006). Lower IGF2 serum 
levels and higher body weight and height was found in GG (ancestral allele) 
homozygotic men of the IGF2 ApaI (rs680) polymorphism whereas the genotype effect 
was not observed in women (Sayer et al., 2002). Results of O'Dell et al. (1997) 
confirmed these genotype effects in men, whereas women were not included in the 
analysis. Muscle performance (strength parameters) was found to be higher in GG 
homzygotes of the IGF2 ApaI (rs680) polymorphism only in women but not in men 
(Schrager et al., 2004). 
However, gender differences were partly observed concerning different gene variants 
but study results lack a conclusive explanation. An impact of the ACTN3 R577X 
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polymorphism (rs1815739) on increase in muscle strength in response to resitance 
training was found in females but not in males (Clarkson et al., 2005). In a similar 
strength training study, gender differences of the ACTN3 R577X polymorphism 
(rs1815739) could not be confirmed (Roth et al., 2005). Baseline strength parameters  
were found to be different between female genotype (rs1815739) groups whereas no 
differences were observed in men (Walsh et al., 2008). 
Highly significant differences concerning the between ACTN3 R577X (rs1815739) 
allele frequency was assessed between female sprint and endurance athletes (Yang et 
al., 2003). As the effect could not be confirmed in men, gender effects of the ACTN3 
R577X (rs1815739) genotype on performance were suggested. Contrary, in a sample 
of East and West-African elite athletes and controls, no gender differences of variants 
in the ACTN3 gene (rs1815739) were detected (Yang et al., 2007). 
The effect of the MSTN K153R (rs1805086) on muscle response to resistance training 
was assessed in men oand women (Ivey et al., 2000). As the rare R-allele was only 
found in female individuals, results indicate gender differences concerning the MSTN 
(rs1805086) genotype frequency.  
4.4 The Total Genotype Score (TGS) 
The study aimed to assess combined genetic effects on physical performance because 
it can be considered that not one polymorphism alone but the combination of several 
favorable gene variants causes a real genetic advantage concerning sports 
performance. 
To evaluate polygenetic profiles, Williams and Folland (2008) generated the model of 
the Total Genotype Score (TGS). The model assigned a genotype score for every 
included polymorphism, whereas the preferable genotype for a certain phenotype was 
equated with “2”, the less optimal variant was equated with “0”. Heterozygotes got the 
value “1”. The maximum possible genotype score was calculated by multiplying the 
number of polymorphisms included with 2. The sum of each individual genotype score 
was expressed as part of 100 (Williams & Folland, 2008).   
Although the five polymorphisms analysed in the present study are obviously not 
strongly associated with endurance, the comparison of the TGS between endurance 
athletes and controls would have been of interest. Unfortunately, the selected 
polymorphisms in the IGF1 (rs35767) and IGF2 (rs3213221, rs7924316) genes 
analysed have not adequately been documented and described in published data. As 
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our own data did not highlight any differences in the genotype frequency between 
endurance athletes and controls, it is not obvious weather the polymorphisms favoured 
endurance performance or not, and in the case they did, which variant were the optimal 
one for endurance performance. Therefore, it was impossible to calculate the TGS 
because genotypes cannot reasonably be assigned. Even if the calculation of the TGS 
would have been possible, it cannot be supposed that different TGS between controls 
and athletes were noted because differences in the genotype distribution of any 
analysed polymorphism were not detected either. 
The study population was group according to the alleles of the ACTN3 R577X as well 
as of the MSTN K153R polymorphisms. 4 groups were designed: One with carriers of 
at least one copy of the ancestral allele of both polymorphisms, one with carriers of at 
least one copy of the variant allele of both polymorphisms, and two groups with carriers 
of at least one copy of the variant allele of one polymorphism and at least one copy of 
the ancrestral allele of the second polymorphism (Table 16). Mean PAL values were 
calculated within the groups. Heterozygotes of both polmorphisms are part of each of 
the four groups because they carry every possible allele combination. 
Table 16: ACTN3 R577X and the MSTN K153R polymorphisms and PAL 
Allele of the ACTN3 R577X 
polymorphismus (at least 
one copy; X = variant allele) 
Allele of the MSTN K153R 
polymorphismus (at least 
one copy; R = variant allele) 
PAL (mean ± SD) 
ACTN3-R + MSTN-K 1.86 ± 0.366 
ACTN3-R + MSTN-R 1.54 ± 0.141 
ACTN3-X + MSTN-K 1.85 ± 0.374 
ACTN3-X + MSTN-R 1.57 ± 0.218 
It is remarkable that in the groups with carriers of the MSTN K153R variant allele (R) 
the PAL is distinctly lower than in the other two groups. The R-allele of the MSTN 
K153R polymorphism is associated with power athlete status, the effect on endurance 
performance are dicussed controversialy (chapter 2.1.3.1, 4.2.5). In the present study 
population, only four individuals carried at least one copy of the very rare R-allele 
(Table 15, p. 49). None of them was classified as athlete, whereas all genotyped 
athletes were homozygotic for the ancestral K-allele of the MSTN K153R 
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polymorphism. Therefore, the lower PAL values in the groups with carriers of the R-
allele (MSTN K153R polymorphism) are the logical result. The PAL values in the other 
two groups (with carriers of the K-allele of the MSTN K153R polymorphism) are 
compareable with the mean PAL values of the whole study population, which is 1.87 ± 
0.380.  
No endurance athletes carried at least one copy of the variant allele (R) of the MSTN 
K153R polymorphism, which is in accordance with outcomes of other investigations 
(Gonzalez-Freire et al., 2008; Muniesa et al., 2008; Ruiz et al., 2009) but it might also 
be only the result of the very low allele frequency (Table 14, p. 47; chapter 4.2.5). 
Williams & Folland (2008) calculated the hypothetical preferable TGS for endurance 
performance inclunding 23 polymorphisms. The probability for an individual of the 
whole world´s population to possess the optimal genetic profile concerning the 23 from 
Williams and Folland selected polymorphisms was 0.0005%. The calculation 
documents that genetic predisposition is the basis for excellent physical performance 
but many other factors must be co-determining for success. The same  assumption is 
confirmed by the outcomes of Santiago et al. (2009). Seven candidate polymorphisms 
for better endurance performance using the TGS were analysed in 39 excellent and 15 
national-class Caucasian lightweight rowers. The polygenetic profiles did not differ 
between rowers of the different levels. However, there was a trend observable that 
rowers had a better polygenetic profile indicated by a higher TGS than control subjects 
(Santiago et al., 2009). The comparison of 46 excellent endurance athletes and 123 
Caucasian controls highlighted significantly higher TGS values in the athletes than in 
the controls (Ruiz et al., 2009). Polymorphisms analysed were the same in both 
researches, namely polymorphisms in the ACE, the ACTN3, the peroxisome 
proliferators-activated receptor γ coactivator 1α, the creatine kinase, the adenosine 
monophosphate deaminase and the hereditary haemochromatosis gene (Ruiz et al., 
2009; Santiago et al., 2009). Significance of results is limited because the seven 
selected candidate gene polymorphisms are only a part of genes and polymorphisms 
involved determining endurance performance (Williams & Folland, 2008; Ruiz et al., 
2009; Santiago et al., 2009).  
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5 Conclusion 
The aim of the study was to compare genotype frequencies of five candidate 
polymorphisms in cohorts of different activity level.  
In recent years, the number of polymorphism discussed to influence fitness phenotypes 
and physical performance has emerged (Rankinen et al., 2006a). Despite many 
investigations according to the impact of various polymorphisms on physical 
performance were done, uncertainty remains concerning the effective influence of a 
certain gene variant on a certain phenotype (Savulescu & Foddy, 2005; Rankinen et 
al., 2006a). 
The ACTN3 R577X polymorphism (rs1815739) causes a loss of function in the ACTN3 
protein, which occurs in skeletal muscle (North et al., 1999; MacArthur & North, 2004). 
The RR genotype is the ACTN3 positive one and evidently influences performance in 
sprint competitions (Yang et al., 2003; Druzhevskaya et al., 2008; Papadimitriou et al., 
2008; Massidda et al., 2009).  The impact of the polymorphism on endurance 
performance is indistinct (Niemi & Majamaa, 2005; Lucia et al., 2006; Yang et al., 2007; 
Eynon et al., 2009).  
The K153R polymorphism (rs 1805086) in the MSTN gene affects the expression of the 
negative growth factor myostatin (McPherron et al., 1997; McNally, 2004). Effects on 
strength performance were discussed but results are uncertain, at least due to the very 
low frequency of the RR variant in certain populations (Ferrell et al., 1999; Seibert et 
al., 2001; Thomis et al., 2004). The impact of the polymorphism on endurance 
performance was assessed, too. There are references that indicate a favourable role of 
the KK genotype but outcomes are inconsistent (Gonzalez-Freire et al., 2008; Muniesa 
et al., 2008; Ruiz et al., 2009; Santiago et al., 2009). 
Variants in the IGF1 and IGF2 genes in the context of physical performance have 
hardly been analysed although polymorphisms might influence the function of IGF1 and 
IGF2 as growth hormones and therefore physical performance. Devaney et al. (2007) 
analysed the effects on strength outputs and strength training respose of a number of 
polymorphisms in the IGF1 and IGF2 genes. Some associations were found but results 
were difficult to be interpreted evidently.  
244 volunteers donated their DNA for genotyping of the ACTN3 R577X (rs1815739) 
polymorphism, of the MSTN K153R polymorphism (rs1805086), and of variants in the 
IGF1 (rs35767) and the IGF2 (rs 3213221, rs7924316) gene, respectively. All 
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participants gave written informed consent to the analyses and the study protocol was 
approven by the local ethic committee. DNA was isolated from saliva, which was 
collected using mouthwash. DNA was isolated using a prepared isolation kit from 
Qiagen. Allelic discrimination was assessed using real-time PCR and test kits from 
Applied Biosystems. Statistical analyses were calculated in SPSS for Windows using 
the significance level α = 0.05. 
48% of the probands were classified as active, meaning they averagely exercised more 
than 3 hours per week. 36% were sedentary (<3 hours exercise/week). 16% were 
endurance athletes competing on a national or international level.  
Differences in the genotype distributions between cohorts could not be detected in any 
of the five analysed polymorphisms. Additionally, genotype frequencies were compared 
between the quartiles of physical activity indicated by the PAL value. Differences could 
not be observed, either. No gender differences were detected. 
Whereas the effects of the ACTN3 R577X (rs1815739) and the MSTN K153R 
(rs1805086) on endurance performance are contrary discussed in present data, no 
results dealing with variants in the IGF1 (rs35767) and in the IGF2 (rs3213221, 
rs7924316) gene have been published yet.  
Although the control group had an acceptable sample size, the athlete group was 
rather small for genetic analysis. In fact, it is difficult to get an elite athlete sample from 
very homogenous sport disciplines, which is also large enough to detect genetic 
effects, especially in Austria. The national ski team might have been the best possible 
Austrian athlete cohort. Moreover, alpine skiracers have not been the object of genetic 
analyses and findings would have been helpful in the discussion weather strength or 
endurance is the dominating skill in alpine skiing disciplines.    
Negative results concerning the effects of the analysed polymorphisms might indicate 
that the impact of these variants on sport performance was overestimated. Success in 
competition is multifactorial and genetic predisposition is only one part. As we cannot 
exactly assess the extent of genetics, neither be sure about the direction of genetic 
effects, every result is helpful in this large field of research.  
On the other hand, the sample might have been too inhomogenous to highlight genetic 
effects. In fact, large enough sample cohorts and a very rigorose classification of 
sample cohorts were the necessary fundament for the prediction of significant genetic 
effects. Requirements that were not completely met by this analsis, neither by many 
Conclusion 
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other published works. Often they simple cannot be achieved. It is important to 
evaluate results of genetic analyses in the context of the used sample population as, 
for example, the occurrence of the minor allele highly differs between different ethnic 
groups. Ethnic effects might have an impact on the interpretation of outcomes.  
To sum up, present data indicates that the ACTN3 R577X (rs1815739) polymorphism, 
the MSTN K153R polymorphism (rs1805086), and variants in the IGF1 (rs35767) and 
the IGF2 (rs 3213221, rs7924316) gene do not influence endurance performance in 
Austrians because the genotype distribution was not different to the control cohort. 
Polygenetic profiles are more useful to be analysed because it is evident that not one 
polymorphism alone decides about success or failure in competition but combined 
gene effects are critical or at least additive for success in competiton. However, present 
data did not allow the calculation of the Total Genotype Score because advantegous 
genotypes could not be identified. Complementary effects of the ACTN3 R577X 
(rs1815739) and the MSTN K153R (rs1805086) polymorphism on the PAL value were 
difficult to interpret due to the very low frequency of the rare R-allele of the MSTN 
K153R (rs1805086) polymorphism.  
Although the knowledge about genetic predisposition for and the impact of gene 
variants on sport performance is advanced by current works with analyses of larger 
cohorts and highly excellent athletes, future research is needed to get evident data. 
Conclusive data on genetic variants and their effects on performance-related 
phenotypes would complement possibilities in talent scouting and allow developing 
individual training schedules – for elite athletes as well as for sedentaries and 
recreational sportspeople.  
Summary 
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6 Summary 
The study aimed to assess differences of the genotype frequency of five candidate 
polymorphisms in cohorts of different activity level in the context of a larger study on 
genetics and physical performance. Analysed polymorphisms were the ACTN3 R577X 
(rs1815739) polamorphism, the MSTN K153R (rs1805086) polymorphism as well as 
variants in the IGF1 (rs35767) and the IGF2 (rs3213221, rs7924316) gene. It was 
hypothesised that genotype frequencies differ between study cohorts; especially it was 
supposed to find different genetic profiles in athletes.  
DNA was isolated of saliva samples, which were collected using mouthwash. Samples 
were genotyped using TaqMan® SNP Genotyping assays and real-time PCR. All 
participiants gave written informed consent and the study was approven by the local 
ethics committee.  
244 probands were classified as sedentary (<3 hours exercise/week; 36%), active (>3 
hours exercise/week, 48%) and athletes (competing on national or international level of 
different sport disciplines, 16%). Adittionally, the whole study group was devided 
(quartiles) according to the activity level indicated by the PAL, which was assessed 
using a Physical Activity Questionnaire. Group differences were calculated on the 
significance level α = 0.05 using SPSS for Windows. 
Differences in the genotype distributions of any of the five analysed polymorphisms 
were not detected, either between the cohorts “sedentary”, “active” and “athletes” or 
between quartiles of different physical activity. Gender differences could not be 
observed. 
Results indicate that the analysed polymorphisms do not harbour any advantage for 
endurance performance in Austrians. The calculation of polygenetic effects was 
intended but not possible.  
Assessed genetic variants are rather associated with strength and power parameters, 
whereas their impact on endurance performance is discussed controversely, and even 
unexplored, respectively. Present results contradict a possible impact of the five 
analysed polymorphism on endurance performance but future research is reasonable.
Zusammenfassung 
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7 Zusammenfassung 
Die Verteilung der genetischen Varianten ACTN3 R577X (rs1815739), MSTN K153R 
(rs1805086),  sowie Varianten im IGF1 (rs35767) und IGF2 (rs3213221, rs7924316) 
Gen wurde in Gruppen unterschiedlicher körperlicher Aktivität im Rahmen eines 
größeren Projekts zum Einfluss genetischer Varianten auf die Lesitungsfähigkeit 
bestimmt. Es wurde vermutet, dass sich die Gruppen in der Häufigkeit der 
verschiedenen Genotypen unterscheiden. Insobesondere wurde angenommen, in der 
Athletengruppe Genotypenunterschiede zu finden.  
DNA wurde aus mittels Mundspülung gesammelten Speichelproben isoliert. Die 
Alleleverteilung wurde mittels TaqMan® SNP Genotyping Tests und Real-Time PCR 
bestimmt. Alle Probanden erklärten sich schriftlich mit der Untersuchung einverstanden 
und die Studie wurde von der lokalen Ethikkommission genehmigt. Die Stichprobe 
wurde in die Gruppen „Untrainierte“ (<3 Stunden Bewegung/Woche; 36%), „Aktive“ (>3 
Stunden Bewegung/Woche, 48%) und „Athleten“ (Mittel- und LangstreckenläuferInnen 
und StraßenradfahrerInnen auf nationalen und internationalen Niveau) geteilt. 
Zusätzlich wurden die Quartilen, aufgeteilt nach dem PAL als Indikator für körperliche 
Aktivität (erhoben mittels Fragebogen zur körperlichen Aktivität), miteinander 
verglichen. Gruppenvergleich wurden mit SPSS für Windows auf einem 
Signifikanzniveau α = 0.05 durchgeführt. 
Unterschiede hinsichtlich der Genotypen-Häufigkeit zwischen den Probandengruppen 
bzw. der Aktivitätsquartilen konnten bei keinem der untersuchten Polymorphismen 
festgestellt werden. Geschlechtsunterschiede wurden nicht beobachtet. 
Die vorliegenden Ergebnisse weisen darauf hin, dass keiner der untersuchten 
Polymorphismen die Ausdauerleistungsfähigkeit in ÖsterreicherInnen begünstigt. Die 
Berechnung polygenetischer Effekte war angedacht, jedoch leider nicht möglich. 
Der derzeitigen Datenlage zufolge, scheinen die ausgewählten genetischen Varianten 
eher Einfluss auf die Schnelligkeits- und Kraftleistung zu haben, die Begünstigung der 
Ausdauerleistungsfähigkeit durch eine Ausprägung der Polymorphismen wird aber 
kontrovers diskutiert bzw. ist noch nicht erhoben worden. Die vorliegenden Daten 
sprechen gegen einen Einfluss der fünf analysierten Polymorphismen auf die 
Ausdauerleistung. 
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